[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 44636
1. Casagrande R, Georgetti SR, Verri WA, Jabor JR, Santos AC, Fonseca MJ: Evaluation of functional stability of quercetin as a raw material and in different topical formulations by its antilipoperoxidative activity. AAPS PharmSciTech; 2006 Mar;7(1):E64-E71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no detectable loss of activity during 182 days (6 months) of storage at all tested temperatures (4°C, room temperature [RT], 37°C, and 45°C) for the raw material.
  • In conclusion, the results suggest that the activity of quercetin depends on iron chelation, and its posible usefulness as a topical antioxidant to prevent oxidative stress-induced skin damage depends on maintaining its antilipoperoxidative activity stored at RT, which avoids special storage conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1994 May;102(5):671-5 [8176246.001]
  • [Cites] Int J Cosmet Sci. 1995 Jun;17(3):91-103 [19245494.001]
  • [Cites] Free Radic Biol Med. 1999 Dec;27(11-12):1313-23 [10641726.001]
  • [Cites] Biochem Pharmacol. 1998 Oct 15;56(8):935-43 [9776303.001]
  • [Cites] Methods Cell Biol. 1978;20:411-81 [151184.001]
  • [Cites] Asia Pac J Clin Nutr. 1999 Mar;8(1):53-63 [24393737.001]
  • [Cites] Methods Enzymol. 1990;186:343-55 [2172711.001]
  • [Cites] Free Radic Biol Med. 1998 Jun;24(9):1355-63 [9641252.001]
  • [Cites] Chem Biol Interact. 1989;71(1):1-19 [2550151.001]
  • [Cites] Free Radic Biol Med. 2000 Aug;29(3-4):375-83 [11035267.001]
  • [Cites] J Biol Chem. 1949 Feb;177(2):751-66 [18110453.001]
  • [Cites] Toxicology. 2000 Nov 23;154(1-3):21-9 [11118667.001]
  • [Cites] Biochem Pharmacol. 1989 Sep 1;38(17):2859-65 [2476132.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):2929-34 [8621682.001]
  • [Cites] Methods Enzymol. 1978;52:302-10 [672633.001]
  • [Cites] Biochem Pharmacol. 1993 Jan 7;45(1):13-9 [8424806.001]
  • [Cites] Br J Pharmacol. 2002 May;136(1):136-42 [11976278.001]
  • [Cites] Biochem J. 1987 Apr 1;243(1):55-9 [3038086.001]
  • [Cites] Free Radic Biol Med. 1995 Oct;19(4):481-6 [7590397.001]
  • [Cites] Free Radic Biol Med. 2001 Oct 1;31(7):869-81 [11585705.001]
  • [Cites] Free Radic Biol Med. 1998 Jun;24(9):1455-61 [9641263.001]
  • (PMID = 28290025.001).
  • [ISSN] 1530-9932
  • [Journal-full-title] AAPS PharmSciTech
  • [ISO-abbreviation] AAPS PharmSciTech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; antioxidant / flavonoids / lipid peroxidation / quercetin / stability
  •  go-up   go-down


2. Jia KD, Zou ZY, Lv DY: The Value of Survivin Gene and Proliferation of Hepatocytes in Screening for Hepatocellular Carcinoma. Gastroenterology Res; 2009 Dec;2(6):333-337
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prospective surveillance programs on patients with liver diseases based on repeat ultrasound examinations of liver and serum α-fetoprotein (AFP) detection were reported having the probability of finding hepatocellular carcinoma (HCC) at its early stage, but it is time-consuming and not cost-effective.
  • To improve the effectiveness and cost-effective of HCC surveillance program, close monitoring has been focused on patients with liver cirrhosis who have particularly high risk of HCC development.
  • METHODS: Total RNA was extracted from fresh specimens of HCC and liver cirrhosis.
  • Survivin mRNA amplification was performed by reverse transcription polymerase chain reaction (RT-PCR).
  • RESULTS: RT-PCR was performed in 17 HCC and 10 liver cirrhosis specimens, 11 HCC specimens showed 344bps molecular survivin DNA band in 1% agarose electrophoresis, but none of liver cirrhosis specimens showed positive band.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990202.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Hepatocellular carcinoma / Liver cirrhosis / Proliferation / Proliferation cell nuclear antigen / Survivin gene
  •  go-up   go-down


3. Stravitz RT: Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist. Gastroenterol Hepatol (N Y); 2006 May;2(5):346-354

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The referral of a patient with cirrhosis to a liver transplant center for evaluation is usually made by a local gastroenterologist.
  • The local gastroenterologist must also fully appreciate what constitutes a timely referral of a patient to a liver transplant center and the consequences of late referral.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2003 Aug;39(2):208-14 [12873817.001]
  • [Cites] Lancet. 2003 Nov 29;362(9398):1819-27 [14654322.001]
  • [Cites] J Hepatol. 2003 Jan;38(1):51-8 [12480560.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):937-40 [12949737.001]
  • [Cites] Gastroenterology. 1987 Aug;93(2):234-41 [3297907.001]
  • [Cites] Hepatology. 1990 Aug;12(2):273-80 [2391068.001]
  • [Cites] Semin Liver Dis. 2005;25(2):181-200 [15918147.001]
  • [Cites] Hepatology. 1992 Jul;16(1):132-7 [1352268.001]
  • [Cites] Am J Gastroenterol. 2002 Feb;97(2):435-9 [11866284.001]
  • [Cites] Hepatogastroenterology. 1997 Jul-Aug;44(16):1172-81 [9261620.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1171-4 [7557868.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):734-44 [11922571.001]
  • [Cites] Scand J Gastroenterol. 1987 Jan;22(1):117-23 [3563404.001]
  • [Cites] J Hepatol. 2003 Mar;38(3):266-72 [12586291.001]
  • [Cites] Liver Transpl. 2005 Mar;11(3):249-60 [15719412.001]
  • [Cites] Semin Liver Dis. 2005;25(2):201-11 [15918148.001]
  • [Cites] Semin Liver Dis. 2005;25(2):143-54 [15918143.001]
  • [Cites] Hepatology. 2001 Feb;33(2):464-70 [11172350.001]
  • [Cites] Liver Transpl. 2005 Jun;11(6):679-83 [15915490.001]
  • [Cites] Gut. 1982 Jan;23(1):1-7 [7035298.001]
  • [Cites] Drugs. 1995 Mar;49(3):467-84 [7774516.001]
  • [Cites] Hepatology. 1995 Sep;22(3):753-8 [7657279.001]
  • [Cites] J Hepatol. 1986;3(1):75-82 [3745889.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1407-32 [15880505.001]
  • [Cites] J Hepatol. 2005;42 Suppl(1):S65-74 [15777574.001]
  • [Cites] Liver Transpl. 2005 Feb;11(2):124-33 [15666386.001]
  • [Cites] Hepatology. 2004 Mar;39(3):841-56 [14999706.001]
  • [Cites] Hepatology. 2002 Jan;35(1):105-9 [11786965.001]
  • [Cites] Clin Liver Dis. 2001 Aug;5(3):645-63 [11565135.001]
  • [Cites] Hepatology. 2001 Jul;34(1):28-31 [11431730.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):941-66 [12949738.001]
  • [Cites] N Engl J Med. 1988 Oct 13;319(15):983-9 [3262200.001]
  • [Cites] Am J Transplant. 2003 Dec;3(12):1481-7 [14629278.001]
  • [Cites] Hepatology. 1997 Jan;25(1):63-70 [8985266.001]
  • [Cites] Gut. 1979 Feb;20(2):133-6 [311747.001]
  • [Cites] Liver Transpl. 2002 Jul;8(7):582-7 [12089709.001]
  • [Cites] Liver. 1999 Jun;19(3):188-92 [10395037.001]
  • [Cites] Miner Electrolyte Metab. 1993;19(6):362-7 [8164617.001]
  • [Cites] Alcohol Clin Exp Res. 2004 Mar;28(3):468-79 [15084905.001]
  • [Cites] Semin Liver Dis. 1999;19(4):439-55 [10643628.001]
  • [Cites] Hepatology. 1994 Jan;19(1):72-9 [8276370.001]
  • [Cites] Ann Intern Med. 1989 May 15;110(10):838-9 [2712463.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12 [15508073.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):286-90 [9445408.001]
  • [Cites] Am J Gastroenterol. 2003 Oct;98(10):2268-74 [14572578.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1372-80 [15521006.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):91-6 [12512033.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2193-7 [10445549.001]
  • [Cites] Ann Pharmacother. 2005 Jan;39(1):68-76 [15590870.001]
  • [Cites] Hepatology. 1990 Oct;12(4 Pt 1):716-24 [2210673.001]
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):1968-76 [11467622.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Apr;17(4):462-6 [11982728.001]
  • [Cites] Clin Liver Dis. 2001 Aug;5(3):665-76 [11565136.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1680-5 [1568578.001]
  • [Cites] Hepatology. 1995 Aug;22(2):432-8 [7543434.001]
  • [Cites] Dig Dis Sci. 2001 Dec;46(12):2752-7 [11768269.001]
  • [Cites] Ann Intern Med. 1995 Apr 15;122(8):595-8 [7887554.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1005-14 [15057740.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):579-86 [9247479.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22 [15042359.001]
  • [Cites] Ann Intern Med. 1970 Sep;73(3):393-6 [5455989.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2343-51 [11007240.001]
  • [Cites] Hepatology. 2004 Jul;40(1):65-72 [15239087.001]
  • [Cites] N Engl J Med. 1999 Apr 1;340(13):988-93 [10099140.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):414-9 [10419924.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Nov;222(2):99-112 [10564534.001]
  • [Cites] Gastroenterology. 1981 Apr;80(4):800-9 [6970703.001]
  • [Cites] Hepatology. 2004 Mar;39(3):739-45 [14999692.001]
  • [Cites] Gastroenterology. 1980 Mar;78(3):512-7 [7351289.001]
  • [Cites] Liver Transpl. 2000 Jul;6(4):440-2 [10915165.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):503-8 [10685758.001]
  • [Cites] Transplantation. 2001 Aug 27;72(4):666-70 [11544428.001]
  • [Cites] Hepatology. 1988 Jul-Aug;8(4):966-8 [3391524.001]
  • (PMID = 28289338.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cirrhosis / liver failure / liver transplantation / portal hypertension
  •  go-up   go-down


Advertisement
4. Nakagawa K, Fukuhara N, Kawakami H: A packed building-block compensator (TETRIS-RT) and feasibility for IMRT delivery. Med Phys; 2005 Jul;32(7Part1):2231-2235

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A packed building-block compensator (TETRIS-RT) and feasibility for IMRT delivery.
  • A packed building-block compensator (TETRIS-RT) for IMRT (Intensity Modulated Radiation Therapy) delivery has been proposed.
  • Preliminary film experiments have shown that an additional leakage dose through the rounded edges of the ten-layered x-ray absorbing blocks was 0.9% of the delivered dose with a total shielded dose ratio of 10% including the peak leakage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28493568.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Calibration / Dosimetry / Field size / IMRT / Image quality / Intensity modulated radiation therapy / Linear accelerators / Medical treatment planning / Multileaf collimators / Wedges and compensators / X-ray absorption near edge structure / X-ray scattering / X-rays / block / compensator / dosimetry / image resolution / intensity modulation / linear accelerators / radiation therapy
  •  go-up   go-down


5. Moeller KK, Coventry S, Jernigan S, Moriarty TM: Atypical teratoid/rhabdoid tumor of the spine. AJNR Am J Neuroradiol; 2007 Mar;28(3):593-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the spine.
  • SUMMARY: Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant central nervous system neoplasm usually seen in young children and infants.
  • Prognosis for AT/RT is poor, with most patients dying within 1 year of presentation.
  • AT/RT most commonly occurs intracranially.
  • We present a case of AT/RT occurring in the thoracolumbar spine of a child and review available clinical and imaging findings in previously reported cases of spinal AT/RT.
  • [MeSH-major] Magnetic Resonance Imaging. Rhabdoid Tumor / pathology. Spinal Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353344.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Tez S, Köktener A, Güler G, Ozişik P: Atypical teratoid/rhabdoid tumors: imaging findings of two cases and review of the literature. Turk Neurosurg; 2008 Jan;18(1):30-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumors: imaging findings of two cases and review of the literature.
  • Atypical teratoid/rhabdoid tumor (AT/RT) is a malignant embryonal central nervous system (CNS) tumor, manifesting in children, and composed of rhabdoid cells, with or without fields resembling a classical primitive neuroectodermal tumor (PNET), epithelial tissue and neoplastic mesenchyme.
  • Around 200 cases of CNS AT/RT have been documented in the literature.
  • Although the clinical and pathological findings have been defined in large series previously, and AT/RT has become increasingly recognized, awareness of typical AT/RT is important in making the correct diagnosis of this uncommon but probably underdiagnosed entity.
  • Neuroradiologists rarely mention AT/RT in their differential diagnosis and this paper presents two additional cases in which clinical and pathological findings are combined with neuroradiological presentation.
  • [MeSH-major] Brain Neoplasms / pathology. Magnetic Resonance Imaging. Rhabdoid Tumor / pathology. Teratoma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382974.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 18
  •  go-up   go-down


7. Potter T, Tavernier R, Devos D, Beeumen KV, Duytschaever M: Predictors of Success After a First Circumferential Pulmonary Vein Isolation For Atrial Fibrillation. J Atr Fibrillation; 2009 Apr-May;1(6):161
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <b>Conclusions:</b> (1) Using the "circumferential pulmonary vein isolation" approach, the first catheter ablation leads to resolution of arrhythmia in ≈ 70% of symptomatic AF patients. (2) Independent predictors for freedom of AF after initial CPVI are duration of AF history and 3D LA volume. (3) Due to considerable overlap between failures and successes, these parameters can not be used to identify patients who should not undergo CPVI or in whom an additional ablation beyond CPVI is required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Heart Rhythm. 2005 Jan;2(1):42-8 [15851264.001]
  • [Cites] Circulation. 2002 Mar 5;105(9):1077-81 [11877358.001]
  • [Cites] Circulation. 2000 Nov 14;102(20):2463-5 [11076817.001]
  • [Cites] Circulation. 2003 Nov 11;108(19):2355-60 [14557355.001]
  • [Cites] JAMA. 2005 Jun 1;293(21):2634-40 [15928285.001]
  • [Cites] J Am Coll Cardiol. 2005 Jan 18;45(2):285-92 [15653029.001]
  • [Cites] Circulation. 2001 Nov 20;104(21):2539-44 [11714647.001]
  • [Cites] Circulation. 2004 Oct 12;110(15):2090-6 [15466640.001]
  • [Cites] Circulation. 2004 Jan 27;109(3):327-34 [14707026.001]
  • [Cites] Circulation. 1999 Sep 14;100(11):1203-8 [10484541.001]
  • [Cites] J Heart Valve Dis. 2007 Jan;16(1):76-83 [17315386.001]
  • [Cites] Europace. 2006 Sep;8(9):651-745 [16987906.001]
  • [Cites] J Cardiovasc Electrophysiol. 2006 Mar;17(3):251-5 [16643395.001]
  • [Cites] J Interv Card Electrophysiol. 2006 Apr;15(3):157-63 [16955362.001]
  • [Cites] J Cardiovasc Electrophysiol. 2004 Jun;15(6):692-7 [15175066.001]
  • [Cites] J Am Soc Echocardiogr. 2008 Jun;21(6):697-702 [18187293.001]
  • [Cites] J Cardiovasc Electrophysiol. 2008 Aug;19(8):807-11 [18363688.001]
  • [Cites] N Engl J Med. 1998 Sep 3;339(10):659-66 [9725923.001]
  • [Cites] J Am Coll Cardiol. 2004 Mar 17;43(6):1004-9 [15028358.001]
  • [Cites] Eur Heart J. 2005 Dec;26(23):2550-5 [16183686.001]
  • [Cites] Cardiovasc Res. 2002 May;54(2):230-46 [12062329.001]
  • [Cites] Arq Bras Cardiol. 2007 Feb;88(2):134-43 [17384829.001]
  • [Cites] J Interv Card Electrophysiol. 2006 Apr;15(3):145-55 [17019636.001]
  • [Cites] Europace. 2007 Dec;9(12):1129-33 [17923474.001]
  • [Cites] Heart Rhythm. 2006 Sep;3(9):1024-8 [16945795.001]
  • [Cites] J Am Coll Cardiol. 2002 Jul 3;40(1):100-4 [12103262.001]
  • [Cites] J Cardiovasc Electrophysiol. 2002 Feb;13(2):118-23 [11900284.001]
  • [Cites] J Cardiovasc Electrophysiol. 2006 Sep;17 (9):965-72 [16948740.001]
  • [Cites] Europace. 2005 Mar;7(2):95-103 [15763523.001]
  • [Cites] Europace. 2007 Jun;9(6):335-79 [17599941.001]
  • [Cites] Circulation. 2005 Aug 9;112(6):789-97 [16061740.001]
  • [Cites] Eur Heart J. 2007 Apr;28(7):836-41 [17395676.001]
  • [Cites] J Cardiovasc Electrophysiol. 2006 Oct;17(10):1080-5 [16989649.001]
  • (PMID = 28496618.001).
  • [Journal-full-title] Journal of atrial fibrillation
  • [ISO-abbreviation] J Atr Fibrillation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Savoia P, Quaglino P, Osella-Abate S, Comessatti A, Nard T, Bernengo MG: Tyrosinase mRNA RT-PCR analysis as an additional diagnostic tool for the identification of melanoma cells in biological fluid samples other than blood: A preliminary report. Int J Biol Markers; 2005 Jan - Mar;20(1):11-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tyrosinase mRNA RT-PCR analysis as an additional diagnostic tool for the identification of melanoma cells in biological fluid samples other than blood: A preliminary report.
  • : Reverse transcription polymerase chain reaction (RT-PCR) of tyrosinase mRNA has been applied for the detection of melanoma cells in the peripheral blood, lymph nodes and bone marrow of melanoma patients.
  • We evaluated the diagnostic accuracy of RT-PCR in comparison to standard cytology and immunocytochemistry (ICC) for the identification of melanoma cells in biological fluids other than blood.
  • Tyrosinase expression in the biological fluid sample was compared with the expression determined at the same time in peripheral blood.
  • Clear-cut radiological evidence of disease involvement at the sampling site was found in the five patients with negative cytology/ICC and positive RT-PCR (one CSF; four serous membrane effusions); all patients died of disease progression within four months of sampling.
  • The five patients who were negative for both cytology/ICC and RT-PCR did not show any clinical evidence of disease recurrence at the sampling site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207099.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Flynn RT: Loss of radiobiological effect of imaging dose in image guided radiotherapy due to prolonged imaging-to-treatment times. Med Phys; 2010 Jun;37(6Part1):2761-2769

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of radiobiological effect of imaging dose in image guided radiotherapy due to prolonged imaging-to-treatment times.
  • PURPOSE: Increased use of cone beam CT guidance in image guided radiotherapy has prompted the inclusion of the imaging dose in treatment plans, thus using imaging beams to treat tumors.
  • Sublethal radiation damage repair during τd, the time between imaging and treatment, could reduce the effectiveness of the imaging dose, resulting in tumor underdosage.
  • METHODS: The therapeutic effective dose (TED), which, if delivered using only therapeutic beams, would result in the same tumor cell survival as for both the imaging and therapeutic beams, was derived using the generalized linear-quadratic model.
  • TED and Pd are dependent on α/β, sublethal damage repair half-time (Tr), imaging dose (DI) and dose rate (ḊI), therapeutic dose (DT) and dose rate (ḊT), and τd.
  • For tumors with a Tr of 16 min or greater and α/β of 11 Gy, ⟨TED⟩ dropped below Dp by 0.2% or less.
  • CONCLUSIONS: For prostate tumors receiving a reasonable percentage of 5% of their total dose from imaging beams, the theoretical drop in ⟨TED⟩ relative to Dp was 0.5%.
  • For nonprostate tumors with α/β values of 11 Gy, the theoretical drop in ⟨TED⟩ relative to the reference TED was low at 0.2%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512956.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Cone beam computed tomography / Dose-volume analysis / Dosimetry / Dosimetry/exposure assessment / Drug delivery / IGRT / Intensity modulated radiation therapy / Medical imaging / Medical treatment planning / RBE / Radiation therapy / Radiation treatment / Simulation / Therapeutic applications, including brachytherapy / Therapeutics / X-ray imaging / biological effects of X-rays / cancer / cellular effects of radiation / computerised tomography / cone beam CT / dosimetry / imaging dose / radiation therapy / tumours
  •  go-up   go-down


10. Makuria AT, Rushing EJ, McGrail KM, Hartmann DP, Azumi N, Ozdemirli M: Atypical teratoid rhabdoid tumor (AT/RT) in adults: review of four cases. J Neurooncol; 2008 Jul;88(3):321-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid rhabdoid tumor (AT/RT) in adults: review of four cases.
  • Atypical teratoid/rhabdoid (AT/RT) tumor is a rare, highly malignant tumor of the central nervous system (CNS) most commonly found in children less than 5 years of age.
  • Since its histological appearance can be confused with other tumors, especially in adults, separating AT/RT from other neoplasms may be difficult.
  • Radiographically, two tumors were localized in the right fronto-parietal region, one was frontal and the other was found in the left temporal lobe.
  • Immunohistochemical staining showed that the tumor cells were positive for vimentin and reacted variably for keratin, epithelial membrane antigen (EMA), synaptophysin, neurofilament protein, CD34, and smooth muscle actin (SMA).
  • In adult examples of AT/RT, the diagnosis requires a high index of suspicion, with early tissue diagnosis and a low threshold for investigation with INI1 immunohistochemistry to differentiate this entity from other morphologically similar tumors.
  • Although the prognosis is dismal in pediatric population, long term survival is possible in adult AT/RT cases after surgery and adjuvant radiotherapy and chemotherapy.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Rhabdoid Tumor / metabolism. Rhabdoid Tumor / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18369529.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


11. Ahunbay EE, Peng C, Chen GP, Narayanan S, Yu C, Lawton C, Li XA: An on-line replanning scheme for interfractional variationsa). Med Phys; 2008 Aug;35(8):3607-3615

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel online replanning strategy to correct for interfraction anatomic changes in real time is presented.
  • The proposed SAM-SWO scheme is practically comparable to full-scope reoptimization, but is fast enough to be implemented for on-line adaptive replanning, enabling dose-guided RT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28525032.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed tomography / Cone beam computed tomography / Dose-volume analysis / Dosimetry / IGRT / Intensity modulated radiation therapy / Medical image segmentation / Medical imaging / Multileaf collimators / Optimization / Self assembly / adaptive radiotherapy / image segmentation / interfractional variations / planning / radiation therapy / replanning
  •  go-up   go-down


12. Yang R, Tan X, Thomas AM, Shen J, Qureshi N, Morrison DC, Van Way CW 3rd: Crocetin Inhibits mRNA Expression for Tumor Necrosis Factor-α, Interleukin-1β, and Inducible Nitric Oxide Synthase in Hemorrhagic Shock. JPEN J Parenter Enteral Nutr; 2006;30(4):297-301

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crocetin Inhibits mRNA Expression for Tumor Necrosis Factor-α, Interleukin-1β, and Inducible Nitric Oxide Synthase in Hemorrhagic Shock.
  • The hypothesis of the present study is that treatment with crocetin at the beginning of resuscitation suppresses subsequent expression of messenger ribonucleic acid (mRNA) for tumor necrosis factor (TNF-α), interleukin-1 (IL-1β) and inducible nitric oxide synthase (iNOS).
  • Liver samples were collected for reverse transcription-polymerase chain reaction (RT-PCR) analysis of mRNA (TNF-α, IL-1β, iNOS, and β-actin).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28059007.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Yu CP, Cheung JY, Chan JF, Leung SC, Ho RT: Prolonged survival in a subgroup of patients with brain metastases treated by gamma knife surgery. J Neurosurg; 2005 Jan;102(s_supplement):262-265

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival in a subgroup of patients with brain metastases treated by gamma knife surgery.
  • OBJECT: The authors analyzed the factors involved in determining prolonged survival (≥ 24 months) in patients with brain metastases treated by gamma knife surgery (GKS).
  • METHODS: Between 1995 and 2003, a total of 116 patients underwent 167 GKS procedures for brain metastases.
  • <sup>3</sup> The mean follow-up time was 9.2 months.
  • Certain factors were associated with increased survival time.
  • These were stable primary disease (21 of 23 patients), a long latency between diagnosis of the primary tumor and the occurrence of brain metastases (mean 28.4 months, median 16 months), absence of third-organ involvement, and repeated local procedures.
  • CONCLUSIONS: Aggressive local therapy with GKS, repeated GKS, and GKS plus surgery can achieve increased survival in a subgroup of patients with stable primary disease, no third-organ involvement, and long primary-brain secondary intervals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306476.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; brain metastasis / gamma knife surgery / radiosurgery / survival
  •  go-up   go-down


14. Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, McClain CJ, McClave SA: Obesity, Inflammation, and the Potential Application of Pharmaconutrition. Nutr Clin Pract; 2008 Feb;23(1):16-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Obesity creates a low-grade systemic inflammatory response syndrome (SIRS) that is similar (but on a much smaller scale) to gram-negative sepsis.
  • This process involves up-regulation of systemic immunity, is characterized clinically by insulin resistance and the metabolic syndrome, and puts the patient at increased risk for organ failure, infectious morbidity, and mortality.
  • Through lipotoxicity and cytokine dysregulation, obesity may act to prime the immune system, predisposing to an exaggerated subsequent immune response when a second clinical insult occurs (such as trauma, burns, or myocardial infarction).
  • Specialized nutrition therapy for such patients currently consists of a hypocaloric, high-protein diet.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28056680.001).
  • [ISSN] 1941-2452
  • [Journal-full-title] Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
  • [ISO-abbreviation] Nutr Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Stadler P, Peters O: The importance of radiotherapy in AT/RT patients less than 3 years of age: in regards to Chen et al. (Int J Radiat Oncol Biol Phys 2006;64:1038-1043). Int J Radiat Oncol Biol Phys; 2006 Jul 15;65(4):1273; author reply 1273-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of radiotherapy in AT/RT patients less than 3 years of age: in regards to Chen et al. (Int J Radiat Oncol Biol Phys 2006;64:1038-1043).
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Brain Neoplasms. Rhabdoid Tumor. Teratoma

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 [16406394.001]
  • (PMID = 16798419.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


16. Gupta AA, Al-Hussaini H, Yu C, Griffin A, Tsung V, Stephens D, Blackstein M, Hogg D, Ferguson P, Wunder J: Clinical features, treatment, and outcome in 108 patients with localized, high-grade synovial sarcoma (SS). J Clin Oncol; 2009 May 20;27(15_suppl):10584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features, treatment, and outcome in 108 patients with localized, high-grade synovial sarcoma (SS).
  • METHODS: Between 1986 and 2007, 93 adult (AP) and 15 pediatric (PP) patients were diagnosed with high grade, localized SS at 2 centres in Toronto.
  • Survival distribution functions were estimated by Kaplan-meier and compared using Log-rank test.
  • Sixty-six (61%) patients had large tumours (> 5 cm), 7 (6.5%) had neuro-vascular invasion, and 10 (9.3%) had bone invasion.
  • 76 (82%) AP and 8 (53%) PP received radiation (RT).
  • All patients underwent definitive surgery with gross total resection; 9 patients (8 PP) had positive margins.
  • Patients with tumours > 5 cm had significantly worse EFS (63 ± 6.5%) compared to patients with small tumours (88 ± 5.4%, p=0.02), as did those with bone invasion (47 ± 18 vs.75 ± 4.9, p=0.05).
  • Of 29 who received chemotherapy, 9 (31%) relapsed, and of 79 who did not receive chemotherapy, 23 (29%) relapsed.
  • In patients with tumours >5 cm, relapse occurred in 41% (7/17) of those who received chemotherapy compared to 37% (18/49) in those that received no chemotherapy.
  • CONCLUSIONS: Patients with SS < 5 cm have an excellent chance of cure with surgery and RT.
  • Large tumours and those with evidence of bone invasion have a poor outlook.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963882.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Birdsall TC, Cain L, Martin J, Birdsall SM, Wiersum L, Anderson K, Eden B, Flynn J, Kelly D, Braun DP: The effect of naturopathic and nutritional supplement treatment on tumor response, control, and survival in prostate cancer patients treated with radiation therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16088

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of naturopathic and nutritional supplement treatment on tumor response, control, and survival in prostate cancer patients treated with radiation therapy.
  • This study assessed effects of NNS on tumor response to radiation therapy (RT) in prostate cancer patients (PCpts).
  • METHODS: Of 134 RT-treated PCpts with localized tumors, 69 received NNS (+NNS; median age=62.0 yrs) and 65 did not (-NNS; median age=61.5 yrs).
  • Based on pre-RT PSA, 52low (4-10 ng); 13 intermediate (10-20 ng); and 4 high risk (> 20 ng) PCpts were +NNS and 50, 10, and 5 low, intermediate & high risk PCpts were -NNS.
  • Tumor stages for +NNS were T1c (39%); T2a (44%); T2b (10%); T2c (5%) with 1 T3b tumor and were T1b (3%); T1c (46%); T2a (32%); T2b (12%); and, T2c (5%) with 1 T3a tumor for -NNS cohorts.
  • RT consisted of external beam therapy (4500-5000 cGy) + HDR brachytherapy (600-650 cGy/fraction x 2-3 fractions) administered over 6-8 weeks.
  • All pts were monitored ≥ 24 months post RT.
  • For the +NNS cohort that did receive HT, PSA levels were 6.8, 0.03 and 0.12 ng at pretreatment, nadir and ≥ 24 months followup with median time to nadir = 4.3 months and median followup = 29.2 months.
  • Corresponding values for -NNS cohort were 6.9, 0.03, and 0.11 with median time to nadir = 3.6 months and median followup = 30.5 months.
  • CONCLUSIONS: This study shows that NNS with antioxidant activity do not interfere with clinical response to RT ± HT as definitive treatment for limited stage prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963105.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Brandes AA, Franceschi E, Tosoni A, Fioravanti A, Agati R, Andreoli A, Mazzocchi V, Morandi L, Bartolini S, Ermani M: Change in MGMT methylation status between first and second surgery for recurrence: Clinical implications. J Clin Oncol; 2009 May 20;27(15_suppl):2027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated only patients who met the following inclusion criteria: age ≥18; PS 0-2; two distinct surgical procedures; histological diagnosis of GBM both at first and at second surgery for recurrence; postoperative treatment consisting of: a) radiotherapy (RT) followed by temozolomide (TMZ) until 2005, and b) TMZ concurrent with and adjuvant to RT after 2005; a time interval ≥3 month between first and second surgery.
  • The log-rank test was employed to evaluate the significance of the prognostic variables.
  • The percentages of MGMT methylated cases at first and second surgery were compared using the McNemar test.
  • Moreover, while MGMT methylation status is prognostic at first surgery, it appears to be of no prognostic utility at the time of second surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964599.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Spensley S, Gilmore JA, Kenny J, Dunne M, Clayton-Lea A, Thirion PG: Functional outcome of malignant spinal cord compression treated with radiotherapy alone: A prospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional outcome of malignant spinal cord compression treated with radiotherapy alone: A prospective analysis.
  • : e20623 Background: Malignant spinal cord compression (MSCC) is a major oncological complication.
  • The management of Impending Malignant Spinal Cord Compression (IMSCC) remains unclear.
  • Radiotherapy (RT) is often the sole management of both entities.
  • METHODS: All pts with MSCC and IMSCC treated by RT in our institution were screened for 2 national trials (ICORG 05-03/07-11).
  • The primary tumours were haematological [13 pts], lung [10], prostate [8], renal cell [6] and breast [5].
  • 2D RT was used with varying radiation schedules: 20Gy/5fractions (f) [32 pts], 30Gy/10f [12] and other [10].
  • New sphincter dysfunction after RT was seen in 2 pts with IMSCC.
  • CONCLUSIONS: The functional outcome of MSCC treated by RT alone remains poor, with minimal mobility and sphincter improvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961600.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Spreafico F, Piva L, D'Angelo P, Terenziani M, Collini P, Gandola L, Bianchi M, Tamburini A, Provenzi M, Fossati Bellani F: Are all stage III Wilms tumors the same? Data from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). J Clin Oncol; 2009 May 20;27(15_suppl):10030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are all stage III Wilms tumors the same? Data from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
  • : 10030 Background: Criteria to classifying Wilms tumor (WT) as stage III are much heterogeneous, including factors referring both to tumor biology and surgical skills.
  • Main therapy differences across the trials were the timing of abdominal radiotherapy (RT) (anticipated to 2<sup>nd</sup> week from nephrectomy) and doxorubicin cumulative dose reduction from 360 mg/m<sup>2</sup> to 240 in TW2003.
  • Reasons for stage III as follows: lymph nodes (LN) 40 cases (alone 28 cases, combined with other factors 12); cava vein tumor thrombus 7, peritoneum involvement 8, post-operative gross or microscopic tumor remains 24, pre-operative rupture 9, surgical rupture 17.
  • 36 patients received primary 4-week vincristine/dactinomycin regimen, while the others had up-front nephrectomy.
  • Adjuvant therapy consisted of 8-months vincristine/dactinomycin/doxorubicin + flank 1440 cGy RT (whole abdominal 15 Gy in case of diffuse peritoneal contamination).
  • 7 patients had intensified chemotherapy/RT for diffuse anaplasia.
  • Interval between nephrectomy and RT was 75 days in CNR92 (median) and 33 in TW2003.
  • Overall 16 tumor failure occurred (2 in anaplastic tumors): abdominal relapse 8 (combined to other extra-abdominal site 3), lung 5, tumor progression 2, metacronous tumor 1.
  • 1440 cGy flank RT warranted satisfactory local tumor control.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Tian Y, Hua D, Ji Y, Li X, Liu J, Wang B, Yu D: The patterns of care studies for operable breast cancer in China. J Clin Oncol; 2009 May 20;27(15_suppl):e11607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Four academic levels of radiotherapy (RT) departments, located in the Southeast coast of China, were selected.
  • A pattern of care study, about women with operated BC and post-operative RT during 1999 and 2006, was conducted.
  • As type and extent of surgery and RT, the percentage of conservative treatment was increased from 4% in 1999 to 12% in 2006 (p< 0.05), postmastectomy RT was done for all the others.
  • The time interval from operation to initiation of RT were longer in 2006, the mean was delayed from 23.8 to 43.4 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961055.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Nugent E, Case AS, Zighelboim I, DeWitt L, Thaker PH, Massad LS, Powell MA, Mutch DG, Trinkhaus K, Rader JS: Chemoradiation in locally advanced cervical carcinoma: An analysis of cisplatin administration and other clinical prognostic factors. J Clin Oncol; 2009 May 20;27(15_suppl):e16525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16525 Background: The standard treatment for locally advanced cervical cancer is combination weekly cisplatin and radiotherapy (RT).
  • METHODS: Between January 2004 and May 2007 we identified 118 patients at our institution with locally advanced cervical cancer (stage 1B2-IVA) treated with combined weekly cisplatin (40 mg/m2) and RT from chemotherapy log records.
  • Median RT duration was 50 days and 95% received brachytherapy.
  • 32 recurrences were detected with a median time to progression of 27 months.
  • Additionally, advanced stage, longer time to RT completion, and absence of brachytherapy were associated with decreased OS and PFS (p < 0.05).
  • Higher grade was associated with decreased PFS (p = 0.03) but not OS.
  • Age, race, BMI, tumor size, smoking, histology, and IMRT were not statistically significant for OS or PFS.
  • CONCLUSIONS: Number of cisplatin cycles, stage, grade, time to radiotherapy completion, and brachytherapy, are prognostic of PFS and OS in patients with cervical cancer undergoing treatment with combined cisplatin and RT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960790.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Avallone A, Delrio P, Di Gennaro E, Pecori B, Aloi L, Tatangelo F, Petrillo A, Budillon A, Caracò C, Sandomenico C, Comella P: Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):e14546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts).
  • : e14546 Background: OXA, RTX, 5FU, and LFA during preop pelvic RT produced a high rate of complete (TRG1) or subtotal (TRG2) tumor regression in HR-LARC.
  • BEV might enhance response to chemoradiotherapy (CH-RT), but scheduling of BEV could be critical.
  • Therefore, we added BEV to CH-RT in two different schedules to evaluate their feasibility and activity.
  • According to the Simon's two-stage design, assuming a hypothesis of a 50% TRG1 (α=0.05, β=0.20), at least 6/16 TRG1 should be obtained to continue pts accrual in every schedule.
  • Pts received 3 biweekly courses(c) of OXA (100 mg/m2)/TOM (2.5 mg/m2) on day 1, and 5FU (800 mg/m2)/LFA(250 mg/m2) on day 2 during pelvic RT (45 Gy).
  • Changes of circulating endothelial cells (CECs)assessed by flow cytometry in 17 (7 A; 10 B) pts, and glucose metabolism evaluated by FDG-PET in 27 (15 A; 12 B) pts after 1st c of CT were used as surrogate markers of tumor response.
  • The Mann-Whitney test assessed the differences in CECs and FDG-PET related to schedules.
  • TME was planned 8 wks after CH- RT.
  • All but one pt (A) completed the planned CH-RT.
  • Grade 3/4 neutropenia was the most common toxicity with schedule A (7 pts, 44%), while it never occurred with schedule B.
  • CONCLUSIONS: These data suggest the relevance of BEV scheduling during preop CT-RT to optimize safety and efficacy of the combination treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Conroy T, Ducreux M, Lemanski C, Francois E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Montoto-Grillot C, Peiffert D: Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial. J Clin Oncol; 2009 May 20;27(15_suppl):4033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The addition of an ICT (2 cycles of 5 FU-Cisplatin) and of a higher dose of irradiation boost (HDRT) to CRT were evaluated in a factorial 2X2 arms trial (A= ICT; B=ICT+HDRT; C= Reference arm = Pelvic RT 45 Gy/25 fractions with 2 cycles of 5FU-Cisplatin and a boost of 15 Gy; D= HDRT).
  • The compliance was: 99% for ICT, 100% for pelvic RT-CT, and 96% for the boost.
  • The tumour complete response (+ partial response) at 2 months were: A=78% (+18%), B=86% (+13%), C=74% (+21%), D=74 % (+22%) (NS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961547.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J: Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol; 2009 May 20;27(15_suppl):e13004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG).
  • METHODS: Eligibility included: adult patients with stable or recurrent MG (GBM, anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO]) previously treated with radiation therapy (RT) and with or without chemotherapy; interval of at least two weeks between prior RT, or four weeks between prior chemotherapy; Karnofsky ≥ 60%; and adequate hematologic, renal and liver function.
  • The primary endpoints of this study were to determine the maximum tolerated dose (MTD) of SCH 66336 when administered with TMZ, and the toxicity of this combination.
  • Dose-limiting toxicities were: deep venous thrombosis (1 grade 3); nausea and vomiting (1 grade 3); diarrhea (1 grade 3); elevated ALT (1 grade 3); elevated creatinine (1 grade 3); and fatigue (1 grade 3).
  • CONCLUSIONS: SCH 66336 in combination with TMZ is well-tolerated and shows promising response when administered to patient when stable on TMZ alone or after RT and TMZ.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Elshaikh MA, Abdel Hafeez Z, Lu M, Ibrahim D, El Masry T, Yousef A: The effect of androgen deprivation therapy on CD4/CD8 T cells in HIV-negative patients receiving definitive 3D radiation treatment for their prostate carcinoma: Final report of a prospective study. J Clin Oncol; 2009 May 20;27(15_suppl):11056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of androgen deprivation therapy on CD4/CD8 T cells in HIV-negative patients receiving definitive 3D radiation treatment for their prostate carcinoma: Final report of a prospective study.
  • The aim of this prospective study is to explore the correlation of the absolute CD4/CD8 T cell counts and total testosterone in patients receiving androgen deprivation therapy (ADT) with goserelin acetate and definitive radiation treatment (RT) for their prostate cancer.
  • All patients had a baseline total testosterone level (T), PSA, CD4 and CD8 T cell counts.
  • All patients received 6 months of ADT prior to (baseline) and during RT to the prostate.
  • This effect was more pronounced for CD4 T cells at all time points (p=<0.02).
  • At 24 months, when total testosterone levels were increasing, CD4 and CD8 T cell counts were also following these upward trends.
  • The seen correlation between lower testosterone and decline in CD4 and CD8 T cells was only statistically significant in older patients (>65 years) and was not associated with significant decline in total white blood cell counts.
  • CONCLUSIONS: CD4/CD8 T cell counts are sensitive to changes in total testosterone levels.
  • Lower testosterone levels negatively affecting CD4/CD8 T cells counts at all study time points.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963161.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Cocorocchio E, Vanazzi A, Botteri E, Alietti A, Negri M, Bassi S, Preda L, Travaini L, Peccatori FA: Prognostic role of interim &lt;sup&gt;18&lt;/sup&gt;FDG-PET in Hodgkin lymphoma: A single-center experience. J Clin Oncol; 2009 May 20;27(15_suppl):e19520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 30/65 pts showed good prognosis (defined as IA-IIA, < 3 nodal sites, ERS < 50) and received 4 cycles of VBM followed by involved field (IF) radiotherapy (RT); the remaining 35 pts received hybrid ChlVPP/ABVVP for 6 cycles followed by IF RT in case of bulky disease.
  • Fisher exact test was used to compare percentages between groups.
  • After a median follow-up of 30 months, 3-year freedom from treatment failure was 83% and 62% in pts with negative and positive interim <sup>18</sup>FDG-PET, respectively (Log-rank test p<0.01, Hazard Ratio 4.9 (95%CI 1.4-16.1)).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Durbecq V, Majjaj S, Nogaret J, Sirtaine N, Schobbens J, Noterman D, Hertens D, Filipov V, Larsimont D, Veys I: Use of quantitative RT-PCR assay to predict metastases size of sentinel node from breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):621

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of quantitative RT-PCR assay to predict metastases size of sentinel node from breast cancer patients.
  • : 621 Background: A RT-PCR Assay (GeneSearch, Veridex, LLC), FDA approved and CE marked to detect metastases > 0.2 mm in sentinel lymph nodes (SLNs) of breast cancer patients, has been in clinical use in our institute for 25 months.
  • The assay gives qualitative (negative/positive) results by applying cutoff values to cycle times (Cts) of mammaglobin (MG) and cytokeratin 19 (CK19) (cutoff values = 30 / 31 Cts).
  • RESULTS: Performance of the assay's qualitative results against permanent section H&E was similar for both groups (total N = 458), for a total sensitivity 89% (68/76), specificity 95% (364/382) and overall agreement 94%.
  • Results from this investigational study examining the marker Ct values suggest that the assay may provide valuable individual tumor volume data intra- operatively or post-operatively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961419.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Bruce RH, Hseih HB, Curry DN, Krivacic RT, Lazarus N, Frankel P, Lau S, Somlo G: Multiple biomarker expression in circulating tumor cells (CTCs) from locally advanced/inflammatory (LA/IBC) and metastatic breast cancer (MBC) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):1092

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple biomarker expression in circulating tumor cells (CTCs) from locally advanced/inflammatory (LA/IBC) and metastatic breast cancer (MBC) patients (pts).
  • Cell lines with expression of each marker were used for normalization of the cell intensities, and a scoring system was used to account for relative number and expression levels of markers on the CTCs.
  • We have observed CTCs prior to initiating neoRx in all pts with IBC relative to 39% of all LABC/IBC cases, and in 57% of pts (n:14) with HER-2+ primary BC versus 24% (n = 17) with HER-2- BC .
  • ER status, size, or grade did not predict for CTC detection.
  • Expression of HER-2 and ER was observed on 1 of 3 and 3 of 4 CTC samples; there was discrepancy between the CTC expression profile and HER-2 and ER status of the primary BC in one case each.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961237.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Palmer S, Wallace D, Bonner M, Raggl R, Chapieski L, Janzen L, Knight S, Boyle R, Armstrong C, Gajjar A: A longitudinal study of processing speed among children treated for medulloblastoma (MB), supratentorial primitive neuroectodermal tumor (SPNET), or atypical teratoid rhabdoid tumor (ATRT). J Clin Oncol; 2009 May 20;27(15_suppl):10028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A longitudinal study of processing speed among children treated for medulloblastoma (MB), supratentorial primitive neuroectodermal tumor (SPNET), or atypical teratoid rhabdoid tumor (ATRT).
  • High risk (HR, n = 55) patients received 36 - 39.6 Gy CSI and 3D conformal boost to the primary site to 55.8 -59.4 Gy.
  • Average-risk (AR, n=119) patients received 23.4 Gy CSI, 3D conformal boost to the primary site to 55.8 Gy.
  • Those who had posterior fossa syndrome were excluded (n = 26) resulting in 148 patients who completed 459 neuropsychological evaluations using the Woodcock Johnson Tests of Cognitive Abilities-III over a period of 0.03 -4.94 years postdiagnosis.
  • RESULTS: Multivariate modeling revealed a statistically significant decline in processing speed for those < 7 years of age at time of diagnosis (-3.83 points per year, p = 0.003).
  • Those who were > 7 years at diagnosis did not experience a significant change (.86, NS).
  • HR patients experienced greater declines (-.82) than those who were AR (-0.29), but neither slope was statistically significant.
  • CONCLUSIONS: Young age at diagnosis is a prominent risk factor for processing speed impairment among survivors of pediatric embryonal tumors.
  • This study represents the largest comparison of processing speed ability among patients treated for pediatric embryonal tumors with conventional or reduced dose CSI and adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962588.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. D'Amico AV, Braccioforte MH, Moran BJ, Chen M: Diabetes and the risk of death in men with favorable or high-risk prostate cancer following radiation therapy. J Clin Oncol; 2009 May 20;27(15_suppl):5157

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5157 Background: An increased risk of all cause mortality (ACM) has been observed in patients with cancer who have diabetes mellitus (DM) (JAMA 2008:300:2754-2764).
  • METHODS: The study cohort comprised 7041 men of median age 69.6 years treated with brachytherapy with or without external beam radiation therapy (RT) between 10/97 and 7/07.
  • The hazard ratios (HR) and 95% Confidence intervals (CI) reported were adjusted for age, extent of RT, history of myocardial infarction (MI), use of HT and known PC prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964473.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Dziggel L, Veninga T, Haatanen T, Lohynska R, Schild SE, Schild SE, Rades D: Scoring systems predictive of survival and local control of patients irradiated for brain metastases. J Clin Oncol; 2009 May 20;27(15_suppl):2075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scoring systems predictive of survival and local control of patients irradiated for brain metastases.
  • : 2075 Background: This study was performed to create and validate scoring systems to estimate survival and intracerebral local control at 6 months of patients irradiated for brain metastases.
  • METHODS: Data of 1,797 patients irradiated for brain metastases (1,346 whole-brain radiotherapy [WBRT], 131 radiosurgery [RS], 61 WBRT + RS, 259 resection + WBRT) were retrospectively analyzed.
  • Patients were randomly assigned to the test group (N = 1,198) or the validation group (N = 599).
  • In the test group, multivariate analyses (MVA, Cox proportional hazards model) were performed for survival (OS) and local control (LC).
  • Age, performance status, extracranial metastases, interval from tumor diagnosis to RT, and number of brain metastases were significant for OS.
  • Tumor type, performance status, interval from tumor diagnosis to RT, and number of brain metastases were significant for LC.
  • The total score represented the sum of the scores for each factor.
  • For OS, total scores ranged from 15-30 points, and patients were divided into three groups (15-19, 20-25, and 26-30 points).
  • For LC, total scores ranged from 14-27 points, and patients were divided into three groups (14-18, 19-23, and 24-27 points).
  • RESULTS: In the test group, the 6-month OS rates were 9 ± 1% for patients with scores of 15-19 points, 41 ± 2% for those with 20-25 points, and 78 ± 2% for those with 26-30 points (p < 0.0001).
  • The corresponding OS rates in the validation group were 7 ± 2%, 39 ± 3%, and 79 ± 3%, respectively (p < 0.0001).In the test group, the 6-month LC rates were 17 ± 3% for patients with 14-18 points, 49 ± 3% for those with 19-23 points, and 77 ± 2% for those with 24-27 points (p < 0.0001).
  • CONCLUSIONS: Patients irradiated for brain metastases can be grouped with these scores to estimate OS and LC.
  • The OS and LC rates of the validation group were almost identical to the test group, which demonstrates the high validity and reproducibility of both scores.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964378.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Müller BM, Kronenwett R, Hennig G, Weber K, Bohmann K, Winzer KJ, Kristiansen G, Petry C, Dietel M, Denkert C: Quantitative determination of predictive cancer biomarkers in formalin-fixed, paraffin-embedded tissue using a new, fully automated method for RNA isolation. J Clin Oncol; 2009 May 20;27(15_suppl):11032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11032 Background: Personalized cancer therapy depends on the evaluation of tissue-based biomarkers in routine tumor samples.
  • In this study, we present a novel, standardized, and fully automated method for fast isolation of total RNA from FFPE tissue sections.
  • Total RNA was extracted from tissue sections using a new method based on silica-coated iron oxide beads in combination with a specific liquid-handling robot.
  • Yield of RNA was assessed using the Ribogreen assay. mRNA fragment lengths were estimated by reverse transcription PCR (RT-PCR) for G6PDH.
  • Expression of the breast cancer biomarkers ESR1, PGR and HER2 was measured by kinetic RT-PCR (kPCR) and compared with immunohistochemistry (IHC).
  • Investigating three sections of each tumor, we observed a low section-to-section variability of kPCR results (root of mean squared errors of relative ESR1, PGR or HER2 expression in three sections: 0.2-0.5 Ct values).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Tsien C, Nyati M, Chepeha D, Worden F, Helman J, Bradford C, Wolf G, Lawrence T, Eisbruch A: Differential tumor and normal mucosa biomarker modulation by epidermal growth factor receptor (EGFR) inhibition using erlotinib in oral cavity squamous cell carcinoma (OCSCC). J Clin Oncol; 2009 May 20;27(15_suppl):6077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential tumor and normal mucosa biomarker modulation by epidermal growth factor receptor (EGFR) inhibition using erlotinib in oral cavity squamous cell carcinoma (OCSCC).
  • : 6077 Background: Targeted therapy may improve the therapeutic index in locally advanced head neck cancer if differential EGFR inhibition in tumors compared to the normal mucosa is demonstrated.
  • The aim of this pilot study was to determine if there are differences in biomarker modulation between tumor and the normal mucosa and confirm our initial preclinical findings regarding EGFR degradation.
  • METHODS: Patients with primary OCSCC requiring surgical resection had normal mucosa and tumor biopsies prior to a test course of erlotinib.
  • Repeat tumor and normal mucosal biopsies were obtained at the time of surgical resection to evaluate the effect of the EGFR inhibitor on both tumor and the normal mucosa.
  • Changes in known preclinical markers of EGFR activity (phospho, total EGFR, AKT, STAT3) were measured by immunoblotting assays.
  • RESULTS: 12 pts were enrolled; 7 pts with paired tumor and normal mucosa biopsies.
  • Tumor specimens showed over-expression of EGFR compared to the normal mucosa (p = 0.005).
  • Erlotinib treatment led to marked inhibition of both pEGFR and EGFR protein (p = 0.004 and p = 0.007, respectively) in tumor biopsies.
  • In contrast, we found heterogeneity in EGFR inhibition in the normal mucosa following erlotinib. (p = 0.1 [pEGFR], and p = 0.07 [EGFR)]) We noted dramatic reduced levels of pSrc and pSTAT3 following erlotinib in tumors compared to untreated matched tumor samples.
  • CONCLUSIONS: Differential EGFR inhibition in tumors compared to the normal mucosa, may suggest that the addition of EGFR inhibitors to chemo-RT or accelerated RT, whose dose limiting toxicity is acute mucositis, may select patients who will benefit from targeted therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Zuo Z, Jones DM, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Medeiros LJ, Luthra R, Chen SS: A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of the selected genes was assessed using Applied Biosystems low density reverse transcription quantitative PCR (RT-qPCR) arrays in bone marrow (BM) samples from 27 adult Ph+ ALL patients treated with standard chemotherapy plus a tyrosine kinase inhibitor.
  • RT-qPCR results from a 15 case training set, 5 in each outcome group, identified 9 genes that classified the cases with 100% accuracy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961387.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Obeidat NA, Mullins CD, Onukwugha E, Seal B, Hussain A: Characteristics of elderly metastatic prostate cancer (M1 PC) long-term survivors in the SEER Medicare database receiving androgen-deprivation therapy (ADT). J Clin Oncol; 2009 May 20;27(15_suppl):e17513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17513 Background: ADT remains standard treatment for pts with M1 PC, with radiation (RT) and chemotherapy (CT) providing additional palliation.
  • RESULTS: 2,665 ADT pts were first identified who had median OS of 26 months (95% CI 24.0 - 27.0).
  • Median time to first treatment with ADT was 1 mo in both ST and LT groups.
  • Both ST and LT pts received RT and prostatectomy at similar rates, but LT pts had less comorbidities (p = 0.0008), and were more likely to receive CT (p = 0.0026).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963274.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Sambrook J, Levy AR, Johnston KM, Ricard NJ, Bourgault C, Donato BM, Sheehan FG, Hotte SJ, Chasen MR, Briggs AH: Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada. J Clin Oncol; 2009 May 20;27(15_suppl):e17000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To estimate the incremental cost-utility of cetuximab plus radiotherapy (CxRT) versus cisplatin plus radiotherapy (CsRT) among platinum eligible patients and versus RT alone in platinum ineligible patients in Canada.
  • The perspective adopted was that of a provincial ministry of health or cancer agency.
  • RESULTS: Among all patients (KPS 60-100), the ICERs comparing CxRT to RT were $19,740/QALY (95% CI: $11,122 to $695,295) among platinum ineligible patients and for CxRT vs. CsRT, $99,147/QALY (95% CI: $75,998 to $148,951) among platinum eligible patients.
  • Sensitivity analyses indicated that time horizon and assumptions about CsRT effectiveness had the largest impact on results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961653.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Green RM, Cloughesy T, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB: Bevacizumab for recurrent ependymoma. J Clin Oncol; 2009 May 20;27(15_suppl):2060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2060 Background: Ependymoma is a rare type of glioma, representing less than 5% of brain tumors in adults.
  • Radiotherapy (RT) is commonly administered, but there is no standard chemotherapy.
  • We determined radiographic response (Macdonald criteria) and estimated median time to progression (TTP) and overall survival (OS) by the Kaplan-Meier method.
  • Prior treatment included RT in all and temozolomide in four.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964675.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Yoon HH, Powell M, Murphy K, Montgomery EA, Hafez MJ, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK, ECOG E1201-T1 Study Group: Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol; 2009 May 20;27(15_suppl):4530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed whether SNPs in DNA repair paths are associated with complete pathologic response (pCR) in EAC pts who received C-based CRT followed by surgery.
  • METHODS: Patients and specimens: Pretreatment biopsy or post-CRT resection samples were obtained from pts (EAC, stage II-IVa) treated on a randomized phase II trial, E1201 (n=86), of preop CRT (RT to 45 Gy).
  • Arm A: Preop C 30 mg/m<sup>2</sup> + irinotecan (I) 50 mg/m<sup>2</sup> days (d) 1, 8, 22, 29 with RT.
  • Arm B: Preop C 30 mg/m<sup>2</sup> + paclitaxel (P) 50 mg/m<sup>2</sup> d 1, 8, 15, 22, 29 with RT.
  • Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight (Sequenom) for all SNPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Koutcher L, Fury M, Wolden S, Zhang Z, Mo Q, Zelefsky M, Kraus D, Sherman E, Pfister D, Lee N: Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis. J Clin Oncol; 2009 May 20;27(15_suppl):6042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis.
  • : 6042 Background: Both concurrent CDDP/RT and C/RT have been shown in randomized trials to yield superior disease control compared to RT alone in LAHNC, but no randomized trial has compared them.
  • METHODS: From 3/1/06 - 4/1/08, 175 patients were retrospectively identified who received definitive treatment for LAHNC with CDDP (planned total dose 100 mg/m<sup>2</sup> Q3 weeks X 3) and RT (n = 125) or C (400 mg/m<sup>2</sup> load; 250 mg/m<sup>2</sup> weekly) and RT (n = 50).
  • Patients who received prior RT, additional systemic therapy, and/or surgery to the primary site were excluded.
  • Additional CDDP and C features: male sex, 86 v 78%; stage IV, 70 v 68%; and oropharynx, 78 v 70%.
  • Median RT dose (70 Gy), RT length (46 days), and Karnofsky performance status (KPS) (90%) were the same; alcohol/tobacco use was similar.
  • For OS analysis, the concordance probability estimates were .67 for using drug choice alone and .80 for using drug choice, T stage, RT dose, and KPS.
  • CONCLUSIONS: CDDP/RT and C/RT were used to treat somewhat different populations with LAHNC.
  • The observed superiority of CDDP/RT compared to C/RT in LF, DFS, and OS may reflect patient selection issues.
  • However, preliminary multivariate modeling suggests that CDDP/RT remains the preferred option for fit patients pending further analyses and prospective studies comparing these regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Rosenthal DI, Mendoza T, Cleeland C: Identifying head and neck cancer patients at risk for high symptom burden during treatment. J Clin Oncol; 2009 May 20;27(15_suppl):6066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anderson Symptom Assessment Inventory - Head and Neck module (MDASI-HN) prior to radiotherapy (RT) or chemoradiotherapy (CRT) and again six weeks after treatment began.
  • Cluster analysis was used to identify those who were highly symptomatic due to their disease prior to treatment and those who became highly symptomatic due to treatment.
  • Approximately 54% (50/92) of patients who were not symptomatic at the beginning of treatment became symptomatic at the end of treatment.
  • Patients with moderate to severe pain before beginning treatment are 4 times more likely to be severely symptomatic at the end of treatment (p < 0.009).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961943.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Gruber ML, Raza S, Gruber D, Narayana A: Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicity. J Clin Oncol; 2009 May 20;27(15_suppl):2017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Standard treatment includes surgical resection (SR), radiation (RT), concomitant and adjuvant chemotherapy with temozolomide (TMZ).
  • Our objective is to assess the treatment efficacy, safety and survival in patients with newly-diagnosed GBM treated with RT, TMZ, and bevacizumab in the upfront management.
  • Group A (n = 20) was treated with RT (60Gy) and concomitant TMZ (75mg/m<sup>2</sup> daily for 42 days) with bevacizumab (10mg/kg every 2 weeks), 29 days following surgery, followed by up to six cycles of adjuvant TMZ (150mg/m<sup>2</sup>,daily x 7d, q28 with bevacizumab at 10mg/kg days 8 and 22 of each 28 day cycle.
  • Both groups were followed up until tumor progression (PFS).
  • Post-RT and temodar toxicities include thrombocytopenia (1 patient; Gr 3 and fatigue (3 patient;1 Gr 3), bevacizumab related toxicities with RT include leg ulcer with cellulites (1 patient; Gr 3) and pulmonary embolism with thrombocytopenia (1 patient; Gr 4), hypertension (2 patients; Gr 1), and asymptomatic blood products on MRI (2 patients).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964577.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Billan S, Abdah-Bortnyak R, Mezid F, Bernstein Z, Gez E, Nasrallah H, Kuten A: Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil before concurrent chemoradiotherapy or concurrent cetuximab-radiotherapy in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol; 2009 May 20;27(15_suppl):e17045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study assessed the feasibility of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiotherapy (CHT-RT) or concurrent cetuximab-radiotherapy.
  • METHODS: Induction chemotherapy consisted of TPF (docetaxel 75 mg/m(2), cisplatin 75 mg/m(2), 5-fluorouracil 750 mg/m(2)/d continuous infusion for 96 h) every three weeks, followed by CHT-RT regimen (radiotherapy 70 Gy total dose fractionated at 2Gy per day, 5 days a week concurrently with weekly cisplatin 40 mg/m(2) or cetuximab with loading dose of 400 one week before starting radiotherapy and 250 weekly during the radiotherapy) 4-7 weeks later.
  • RESULTS: Between march 2007 and november 2008, 29 previously untreated patients (19 male and 4 female) with stage III-IV squamous cell carcinoma of the oral cavity, larynx, oropharynx, or hypopharynx were included to the study.
  • The stage distribution was as follows: stage II, 1 patient; stage III, 14 patients; and stage IV, 14 patients.
  • Toxicity from IC included neutropenia Gr III,IV 25%,neutropenic fever 9%, mucositis and diarrhrea Gr III, IV 22% .
  • The toxicity from the concurrent phase included mucositis Gr III-IV in 70% of patients,dermatitis Gr III-IV in 43% and no case of neutropenia Gr III-IV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961767.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Morris RT, Cohn DE, Fowler J, Solomon LA, Vay A, Seward S, Heilbrun L, Smith D, Munkarah AR: Combined weekly docetaxel (D) and gemcitabine (G) for relapsed ovarian cancer (OC) and peritoneal cancer (PC): A multi-institutional phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):5565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • D (40 mg/m2) and G (800 mg/m2) were administered on days 1 and 8 of a 21 day cycle until progression.
  • There were 2 separate 2-stage designs used, one for each stratum: Plat-R and Plat-S, separately for a total planned sample of 62 pts.
  • The primary endpoint was overall response rate (ORR).
  • Twelve pts (41%) experienced grade 3 or 4 neutropenia; two of these pts also had documented infections.
  • Three pts had grade 3 anemia and 6 (21%) had grade 3 thrombocytopenia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962563.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Hassan E, Afqir S, Ismaili N, M'rabti H, Boutayeb S, Elghissassi I: Nasopharyngeal carcinoma at the National Institute of Oncology. J Clin Oncol; 2009 May 20;27(15_suppl):e17055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 468 patients, 88 (19%), and 380 (81%) had T1-T2, and T3- T4 (TNM International Union Against Cancer staging system, 1997), respectively.
  • Seventy-six percent received neoadjuvant multiagent chemotherapy containing cisplatin, followed by radiotherapy (RT).
  • Kaplan-Meier curves were used for evaluation of prognostic factors and were compared using the log-rank test.
  • CONCLUSIONS: Combined modality management using chemotherapy and RT resulted in satisfactory locoregional control and OS in patients with nasopharyngeal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961824.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Rineer J, Schreiber D, Wortham A, Olsheski M, Sroufe R, Sura S, Katsoulakis E, Han P, Choi K, Rotman M: Utilization of radiation therapy in early-stage Hodgkin disease and its impact on survival. J Clin Oncol; 2009 May 20;27(15_suppl):8511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8511 Background: Despite numerous randomized trials confirming the benefit of consolidation radiation therapy (RT) in the management of early stage Hodgkin disease (HD), utilization of RT in this setting remains variable.
  • We performed a population-based analysis to assess the utilization of RT and its impact on overall and cause specific survival.
  • Kaplan-Meier analysis was performed to evaluate the effect of RT on overall survival (OS) and cause-specific survival (CSS).
  • RESULTS: A total of 9729 patients met inclusion criteria.
  • 5352 patients (55%) received RT.
  • RT was more likely to be employed during the early era of treatment, in younger patients, females, non-Blacks, and in NS, mixed cellularity and lymphocyte-rich HD.
  • For the entire cohort, RT was associated with a significant (p<0.001) improvement in OS and CSS (hazard ratio of 0.537 and 0.437, respectively).
  • The benefit of RT for OS and CSS remained significant for all subgroups analyzed including the era of treatment, sex, and age (p≤0.001).
  • CONCLUSIONS: In this large population-based series of early stage HD patients, the use of RT is associated with a significant OS and CSS benefit across all subgroups.
  • Current efforts in clinical trials have aimed at decreasing the utilization of RT among this patient population.
  • The omission of RT from the treatment paradigm, however, appears to be related with diminished survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960874.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Lai A, Nghiemphu P, Green R, Spier L, Peak S, Phuphanich S, Fehrenbacher L, Kolevska T, Polikoff J, Cloughesy T: Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. J Clin Oncol; 2009 May 20;27(15_suppl):2000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2000 Background: Bevacizumab (BV) is a humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF).
  • In this trial, we evaluate the safety and efficacy of BV combined with standard of care radiation (RT) and temozolomide (TMZ) and radiation (RT) for newly-diagnosed GBM.
  • Primary outcome measure is overall survival; the secondary outcome measure is TTP and 12-month survival.
  • Therapy began between 3-5 weeks of surgery with BV (10 mg/kg every 2 weeks), TMZ (75 mg/m2 daily), and external beam RT (30 x 200 Gy) on the same day.
  • Preliminary TTP by Kaplan-Meier analysis is promising compared to that of a UCLA/KP control group of patients that received the conventional RT/TMZ regimen.
  • CONCLUSIONS: Addition of BV to the standard regimen of TMZ and RT for newly-diagnosed GBM is well-tolerated and shows promising efficacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964565.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Salazar LG, Slota M, Wallace D, Higgins D, Coveler AL, Dang Y, Childs J, Bates N, Waisman J, Disis ML: A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer.
  • : 3054 Background: HER2 is overexpressed in 25% of breast cancers and plays a role in the malignant transformation of cells.
  • DNA-based vaccines offer a strategy to immunize against multiple tumor antigens and are able to elicit both CTL and T helper immune responses.
  • A phase I study was conducted to evaluate the safety and immunogenicity of a DNA-based vaccine encoding the HER2 ICD.
  • METHODS: 44 subjects with stage III and IV HER2+ breast cancer in complete remission were enrolled sequentially into 2 vaccine arms (22 subjects/arm) and received 10μg pNGVL3-hICD (Arm 1) or 100μg pNGVL3-hICD (Arm 2).
  • All vaccines were admixed with 100μg GM-CSF and given i.d. monthly for a total of 3 vaccines.
  • Vaccine site biopsies were analyzed for plasmid persistence via RT-PCR, 1 and 6 months after vaccination.
  • Vaccine-related toxicity in both arms was primarily grade I/II; no cardiac or grade IV toxicity was observed.
  • ELISPOT and RT-PCR analysis for Arm 2 are on-going.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Bhide S, Gulliford S, A'Hern R, Hall E, Newbold K, Harrington K, Nutting C: Quantitative estimates of the effects of concomitant chemotherapy on acute dysphagia in patients receiving radical treatment for head and neck cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22134 Purpose: To generate quantitative parameters describing the effect of concomitant chemotherapy on incidence of grade 3 dysphagia (CTCAE v3.0, assisted feeding) using dose response curves in patients receiving radical treatment for head and neck cancer.
  • Patients in the PARSPORT trial received radiation alone (RT).
  • RESULTS: The mean MD<sub>2</sub> to the pharyngeal mucosa were 56Gy and 55.8Gy respectively, in the CRT and RT groups.
  • There was a statistically significant difference of 25% (95% CI: 10-38, p=0.002) in the incidence of G3 dysphagia between the CRT (68%) and RT (43%) groups.
  • Fitting dose response curves to the clinical data yielded parameter values (95% CIs) of MD<sub>50</sub>=46 Gy (42-49), k=4.8 (2.3-7.2) for the CRT group and MD<sub>50</sub>= 58 Gy (55-61), k=3 (1.6-.45) for RT group.
  • Dose response gradients for CRT and RT showed approximately 1.95% and 1.3% increase (respectively) in probability of G3 dysphagia resulting from an increase in mean dose of 1Gy between doses of 30Gy to 70Gy.
  • The observed MD<sub>50</sub> for G3 dysphagia is lower for RT alone (46 Gy vs. 58 Gy).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963581.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Gerard J, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne P, Vendrely V, Conroy T, Francois E, Montoto-Grillot C: Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2. J Clin Oncol; 2009 May 20;27(15_suppl):LBA4007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963298.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Sarkaria JN, Galanis E, Wu W, Giannini C, Jaeckle KA, Doyle L, Uhm J, Brown P, Dietz AB, Buckner J: NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients. J Clin Oncol; 2009 May 20;27(15_suppl):2019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients.
  • We previously demonstrated significant synergy of the mTOR inhibitor sirolimus with RT in glioma xenografts.
  • METHODS: The standard cohorts of 3 design was applied with dose escalation of weekly IV CCI-779 in combination with standard TMZ/RT.
  • CCI-779 was given during both RT (60 Gy)/TMZ (75 mg/m2 daily) and adjuvant TMZ (200 mg/m2 daily x 5 every 28 days).
  • RESULTS: A total of 17 patients were enrolled.
  • CCI-779 therapy during RT/TMZ was well tolerated at dose level 0 (25 mg CCI-779, n = 3) and dose level 1 (50 mg CCI-779, n = 6) with 1 of 9 patients experiencing a DLT (Gr 3 fatigue).
  • Despite reasonable tolerance during RT/TMZ, the overall regimen was associated with a high rate of infection associated with lymphopenia.
  • In contrast to our 18% grade 5 infection rate, only 4% grade 3 (no grade 4/5) infections were observed in 26 other CTEP-sponsored clinical trials involving 1,006 patients treated with CCI-779.
  • Further infections were avoided on this trial after CCI-779 therapy was limited to RT/TMZ.
  • CONCLUSIONS: Although CCI-779 in combination with RT/TMZ was well-tolerated, adjuvant therapy with TMZ/CCI-779 was associated with an increased risk of opportunistic infections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Sharma AD, Cantz T, Vogel A, Schambach A, Haridass D, Iken M, Bleidißel M, Manns MP, Schöler HR, Ott M: Murine Embryonic Stem Cell-Derived Hepatic Progenitor Cells Engraft in Recipient Livers with Limited Capacity of Liver Tissue Formation. Cell Transplant; 2008 Mar;17(3):313-323

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Directed endodermal differentiation of murine embryonic stem (ES) cells gives rise to a subset of cells with a hepatic phenotype.
  • Because transplanted unpurified ES-HPC formed teratomas in the spleen and liver, we applied an albumin promoter/enhancer-driven reporter system to purify ES-HPC by cell sorting.
  • RT-PCR analyses for hepatocyte-specific genes showed that the cells exhibited a hepatic phenotype, lacking the expression of the pluripotency marker Oct4, comparable to cells of day 11.5 embryos.
  • In conclusion, the limited repopulation capacity of ES-HPC is not caused by a failure of primary engraftment, but may be due to an immature hepatic phenotype of the transplanted ES-HPC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880674.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cell transplantation / Embryonic stem cells / Hepatic precursor cells / Metabolic liver disease
  •  go-up   go-down


53. Tan EL, Tan TM, Chow VT, Poh CL: Inhibition of Enterovirus 71 in Virus-infected Mice by RNA Interference. Mol Ther; 2007 Nov;15(11):1931-1938

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EV71 replication was significantly reduced as revealed by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blot.
  • However, the chemically synthesized 29-mer shRNA did not protect the suckling mice from EV71 infections despite being more potent in the in vitro system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182883.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Merimsky O, Soyfer V, Corn B: Hypofractionated radiation therapy for palliation of sarcoma metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e21517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21517 Background: RT is our preferred modality for local palliation of metastatic STS, regardless of systemic chemotherapy.
  • While a protracted course of RT may be given as postoperative adjuvant treatment, a short and intense course of RT is usually needed for rapid palliation and local control of metastatic disease.
  • Sarcomas are usually considered, at best, as moderately radio responsive tumors.
  • RT doses within the range of 60 - 70 Gy are usually needed to be delivered in order to eradicate microscopic disease, while 50 Gy doses are needed for other malignancies such as breast or rectal cancer.
  • METHODS: Seventeen patients, 8 women and 9 men, at a median age of 61 years (range 53-95 years) had symptomatic metastatic sarcoma, and required rapid palliation.
  • In total there were 20 sites of involvement by metastatic disease: trunk (chest wall, groin, axilla)- 13 cases, limb- 7 cases.
  • In 15 cases the RT was the only modality for local palliation and in 5 cases RT was given following metastasectomy with close or involved margins.
  • All the patients were treated by a short and intensive course of administration: 39 Gy were given in 13 fractions of 3 Gy/day, 5 times a week.
  • Tumor progression was seen in the 3 other cases within a period of 2 to 9 months.
  • CONCLUSIONS: The results of this series, although limited in size, point to the safety and feasibility of hypofractionated RT for palliation of musculoskeletal metastases from sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963448.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Mazloom A, Zangeneh AH, Teh BS, Paulino AC: Extraneural metastasis of medulloblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):2065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2065 Background: Medulloblastoma is the most common childhood intracranial tumor to spread extraneurally.
  • Factors analyzed included age, time interval to ENM, CNS involvement at the time of ENM, location of ENM, treatment, and outcome.
  • Of patients with available data regarding location of RT after ENM, 87% of patients received this treatment to the site of ENM.
  • The 1-year OS for patients with and without radiotherapy (RT) after ENM was 58% and 35%, respectively (p = 0.019).
  • For patients without CNS involvement at the time of ENM the 1-year OS for those treated with and without RT was 82% and 51%, respectively (p = 0.030), however RT did not significantly improve OS for those with CNS involvement.
  • 1-year OS of patients with time interval to ENM of <18 months was 25% while those with time interval greater than or equal to 18 months it was 61% (p = 0.001).
  • CONCLUSIONS: Negative prognostic factors for patients with ENM include CNS involvement at the time of ENM, lung or liver involvement, and duration to ENM <18 months.
  • Patients without CNS involvement who received RT after ENM had an OS and DFS benefit compared to those not receiving RT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964691.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Herndon JE 2nd, Kirkpatrick J, Gururangan S, Bailey L, Friedman AH, Friedman HS: Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):2015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM).
  • : 2015 Background: Standard GBM treatment includes TMZ and RT, and results in a median progression-free survival and median survival of 6.9 and 15.8 months, respectively.
  • GBM have high concentrations of vascular endothelial growth factor (VEGF), higher levels are associated with poorer prognosis.
  • This study aims to improve the survival of newly diagnosed GBM patients by incorporating an anti-angiogenic agent with RT and TMZ, and adding a topoisomerase I inhibitor, and an anti-angiogenic agent to TMZ post-RT therapy.
  • METHODS: Patients received standard RT and TMZ at 75 mg/m<sup>2</sup>/day, with BV at 10 mg/kg every 14 days beginning a minimum of 28 days post-operatively.
  • Following the completion of RT, patients received 6 cycles of BV, TMZ and CPT-11.
  • All the patients have completed RT; 40 patients continue to receive BV, TMZ, and CPT-11.
  • Twenty-two patients have completed 6 cycles of BV, TMZ, and CPT-11; 17 of them had a cold PET One patient developed a CNS hemorrhage (grade 2) necessitating stopping BV.
  • Five patients developed thrombocytopenia for which TMZ was held (grade 3, n = 1; grade 4, n = 4).
  • There were no other ≥ grade 3 toxicities, including no wound dehiscence during RT.
  • Twelve patients had tumor progression, and 14 stopped because of toxicity, including: 6 with fatigue; 3 with PEs; 2 with grade 4 thrombocytopenia; the patient with CNS hemorrhage, and one each with a rectal abscess and sepsis.
  • There have been 7 deaths: 5 from tumor progression; one each from sepsis and PEs.
  • CONCLUSIONS: Adding BV to TMZ and RT followed by BV, TMZ with CPT-11 is tolerable and efficacious.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964581.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Rampling R, Sanson M, Taal W, Lai C, Stoffregen C, Munoz M, Gorlia T, Govaerts A, Lacombe D, Van den Bent M: Phase 1 study of LY317615 (enzastaurin) and temozolomide in patients with gliomas - EORTC trial 26054. J Clin Oncol; 2009 May 20;27(15_suppl):e13005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients (pts) with recurrent high-grade glioma or newly diagnosed disease not amenable to radiotherapy (RT) and WHO PS 0-1 were eligible.
  • Dose-limiting toxicity (DLT) was defined by CTCAE 3.0 criteria in the first two cycles as (1) any non haematological toxicity grade 3/4 (2) ANC < 500/mm3 (3) thrombocytopenia grade 3/4 (4) any toxicity reducing drug dose intensity to <80%.
  • 13 pts had received prior RT, seven prior chemotherapy, and two were newly diagnosed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962764.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Kaley TJ, Raizer JJ, Paleologos N, Kewalramani T, Grimm S, Louis DN, Cairncross JG, Abrey LE: Phase II trial of temozolomide (TMZ) followed by myeloablative chemotherapy with autologous peripheral blood progenitor cell rescue (APBPCR) for newly diagnosed anaplastic oligodendroglioma: An Oligodendroglioma Study Group trial. J Clin Oncol; 2009 May 20;27(15_suppl):2055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiotherapy (RT) remains the standard therapy, but not without toxicity.
  • Exploiting the chemosensitivity of these tumors using myeloablative chemotherapy with APBPCR is a potential strategy to defer RT.
  • Patients with surgical gross total resection who maintained response or patients who responded to temozolomide (CR or PR defined as >50% reduction in tumor) were eligible for myeloablative chemotherapy with thiotepa 250mg/m2/day for three days followed by busulfan 3.2mg/kg/day for three days, followed by APBPCR.
  • RESULTS: 19 patients (16 AO, 2 AOA, 1 low-grade oligodendroglioma with radiographic features suggestive of high-grade tumor) with a median age of 42 (28-56) and KPS of 90 (70-100) were enrolled.
  • 2 of the 10 patients who underwent APBPCR recurred, one at 16.1 and one at 34.2 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964668.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Speranza L, De Lutiis MA, Shaik YB, Felaco M, Patruno A, Tete' A, Mastrangelo F, Madhappan B, Castellani ML, Conti F, Vecchiet J, Theoharides TC, Conti P, Grilli A: Localization and activity of iNOS in normal human lung tissue and lung cancer tissue. Int J Biol Markers; 2007 Jul - Sep;22(3):226-231

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent investigations of NO expression in tumor tissue indicated that, at least for certain tumors, NO may mediate one or more roles during the growth of human cancer.
  • We localized iNOS in these tissues by immunohistochemistry and tested the mRNA expression by RT-PCR, the protein level by Western blot, and the protein activity by radiometric analysis.
  • The results demonstrate different expression, localization and activity of iNOS in normal versus tumor tissue.
  • This is suggestive of a role for NO production from iNOS in human lung cancer because high concentrations of this short molecule may transform to highly reactive compounds such as peroxynitrite (ONOO-); moreover, through the upregulator NF-kB, they can induce a chronic inflammatory state representing an elevated risk for cell transformation to cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207135.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


60. Lordick F, Meyer Zum Büschenfelde C, Thuss-Patience P, Röthling N, Geinitz H, Budach V, Schumacher G, Friess H, Siewert JR, Peschel C: Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol; 2009 May 20;27(15_suppl):e15507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
  • Pts received weekly CET 250mg/m2 plus RT 25 x 1.8 Gy (cumulative dose 45 Gy) d1-33.
  • Surgery was scheduled 4-6 weeks after RT.
  • Of 6 pts treated in cohort 3, 1 pt developed grade 3 diarrhea and mucositis.
  • CONCLUSIONS: 2 weeks of CET (400mg/m<sup>2</sup> and 250mg/m<sup>2</sup>) followed by weekly CET (250mg/m<sup>2</sup>) plus OX 50mg/m<sup>2</sup> d1,8,22,29, 5-FU 225 mg/m<sup>2</sup>/d d1-5,8-12,15-19,22-26,29-33 and RT 45 Gy (1.8Gy/f) was shown to be safe as neoadjuvant treatment for locally advanced ESCC.
  • The anti-tumor activity of this regimen is promising and is being further investigated in an ongoing phase II study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962237.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. de Vreeze RS, de Jong D, Nederlof PM, Ruijter HJ, Boerrigter L, Haas RL, van Coevorden F: Multifocal myxoid liposarcoma: Metastasis or second primary? A molecular biological analysis. J Clin Oncol; 2009 May 20;27(15_suppl):10576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal myxoid liposarcoma: Metastasis or second primary? A molecular biological analysis.
  • : 10576 Background: The metastatic or second primary nature of multifocal myxoid/round cell liposarcoma (MRLS), defined as tumor presentation in at least two separate sites before manifestation in the lungs, is a matter of debate with essential clinical consequences.
  • Moreover, in solid tumors, analysis of loss of heterozygozity (LOH) has proven its value for clonality analysis.
  • Using RT-PCR, the detailed molecular characteristics of FUS-CHOP and EWS-CHOP breakpoints were determined.
  • RESULTS: In all patients, tumor sites showed identical FUS-CHOP exon fusion products.
  • In all other patients, LOH analysis was highly suggestive of clonal relation and no evidence for interpretation of a second primary tumor was found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963785.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Rampias T, Sasaki C, Psyrri A: Effect of human papillomavirus (HPV) 16 E6 and E7 gene silencing on epidermal growth factor receptor (EGFR) phosphorylation status in HPV16&lt;sup&gt;+&lt;/sup&gt;oropharyngeal cancer cell lines. J Clin Oncol; 2009 May 20;27(15_suppl):e17006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phospho-EGFR (Tyr<sup>1068</sup>), (Tyr<sup>845</sup>), (Tyr<sup>992</sup>), (Tyr<sup>1045</sup>) and total EGFR protein levels before and after silencing were then analyzed by western blotting in 147T and 090 oropharyngeal cancer cell lines.
  • RESULTS: Quantitative RT-PCR analysis showed reduction in E6/E7 mRNA levels up to 85% the level in uninfected or control shRNA infected cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Pasini F Sr, de Manzoni G, Stievano L, Grandinetti A, Maluta S, Capirci C, Durante E, Bonetti A, Zanoni A, Cordiano C: Effect of neoadjuvant combined modality therapy with weekly docetaxel (D) and cisplatin (P), 5-fluorouracil (5-FU) continuous infusion (c.i.), and concurrent radiotherapy (RT) on pathological response rate in esophageal cancers (EC): A phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of neoadjuvant combined modality therapy with weekly docetaxel (D) and cisplatin (P), 5-fluorouracil (5-FU) continuous infusion (c.i.), and concurrent radiotherapy (RT) on pathological response rate in esophageal cancers (EC): A phase II study.
  • In a phase I study (Pasini et al, Ann Oncol 2005) we demonstrated the feasibility of a novel protocol of neoadjuvant chemoradiation.
  • The primary end point was the pathological response rate, the secondary end points were survival and toxicity.
  • Treatment consisted of D 35 mg/m2 and P 25 mg/m2 d 1,8,15,29,36,43,50,57 plus 5-FU 180 mg/m2 c.i. d 1-21 and 150 mg/m2 c.i. d 29-64; concurrent RT (50 Gy) started on d 29.
  • Surgery was performed 6 to 8 weeks after completion of RT.
  • The overall median survival was 50 mo; median survival times of Others, pTrm, and pCR subsets were 17, 42 months and not reached, respectively (p<0.001).
  • During chemoradiation, grade 3-4 hematological toxicity occurred in 10 pts (13.5%); grade 3-4 non-hematological toxicities occurred in 22 pts (30%), mostly in the last 2 weeks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963008.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Mitsiades N, Schultz N, Taylor BS, Hieronymus H, Satagopan J, Scardino PT, Reuter VE, Sander C, Sawyers C, Scher HI, Prostate Cancer Genome Project Group: Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies. J Clin Oncol; 2009 May 20;27(15_suppl):5002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Gene expression profiles of 30 normal prostate tissue samples, 131 primary prostate carcinomas (PCas) and 16 metastatic PCas, generated using Affymetrix Exon arrays, were interrogated for levels of 40 mRNAs encoding AR, SHBG, 28 enzymes involved in androgen synthesis and 10 enzymes involved in androgen inactivation.
  • For individual tumors, a transcript was considered to be overexpressed or underexpressed when its levels were >2 SDs higher or lower, respectively, than its average levels in normal tissue.
  • RESULTS: Metastatic PCas expressed higher average transcript levels for AR and several steroidogenic enzymes, including SRD5A1 and SRD5A3, than primary PCas and normal prostate tissue.
  • Expression of SRD5A2, CYP3A4, CYP3A5, and CYP3A7 mRNAs was decreased both in primary and metastatic tumors compared to normal prostate tissue.
  • In analysis involving AR and 28 steroidogenic transcripts in individual tumors, all (16/16) metastatic PCas overexpressed at least one transcript (range: 2-14, median: 5 transcripts) compared to normal tissue, while 100/131 (76%) primary PCas overexpressed at least one transcript (range: 2-16, median: 2).
  • Overexpression of AR or steroidogenic enzymes may serve as a biomarker (e.g. by detection via RT-PCR in circulating tumor cells) to predict for sensitivity to these agents and guide patient selection for participation in clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Nguyen PL, Chen MH, Beard CJ, Loffredo M, Renshaw AA, Suh WW, Kantoff PW, D'Amico AV: Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). J Clin Oncol; 2009 May 20;27(15_suppl):5129

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa).
  • : 5129 Background: 6 months of AST+RT was shown to improve survival vs. RT alone in men with unfavorable-risk localized PCa, but it is unknown if this benefit applied to all risk subgroups.
  • METHODS: Among 206 men with clinical T1b-T2b PCa and at least 1 unfavorable feature (PSA>10 or Gleason >=7 or MRI evidence of T3 disease) randomized to 70Gy of RT with or without 6 months of AST, we performed post-randomization subgroup analyses within four subgroups defined by both risk group (high risk [Gleason 8-10 or PSA >20] or intermediate risk [all others]), and by ACE-27 comorbidity level (no/limited comorbidity or moderate/severe comorbidity).
  • Within the 4 subgroups a log-rank test was used to compare Kaplan Meier estimates of survival (requiring p < 0.05/4 or p < 0.0125 to adjust for multiple comparisons) and within the 2 risk groups we used Cox multivariable analysis (MVA) to assess the association of treatment with the risk of death after adjusting for known prognostic factors.
  • In men with no or minimal comorbidity, estimates of survival were significantly higher among those who received AST+RT vs. RT alone, regardless of whether they had intermediate risk disease (90.9 vs. 85.8% at 7yrs, p = 0.009) or high-risk disease (88.9% vs. 51.2% at 7yrs, p = 0.007).
  • In men with moderate or severe comorbidity, no difference in survival was observed after AST+RT vs. RT in intermediate risk (p = 0.2) or high risk (p = 0.5).
  • After adjusting for known prognostic factors, treatment with RT as compared to AST+RT was associated with an increased risk of death in men with intermediate (AHR: 3.0 [95% CI: 1.3 to 7.2]; p = 0.01) and high risk disease (AHR: 3.3 [95% CI: 0.94 to 11.3]; p = 0.06) in a model that adjusted for the interaction between treatment and comorbidity.
  • CONCLUSIONS: Among men with T1b-T2b prostate cancer who have no or minimal comorbidity, the addition of 6 months of AST to RT was associated with improved survival in men with both intermediate risk and high-risk disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964400.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Jagsi R, Abrahamse P, Griggs JJ, Katz SJ: Adjuvant radiotherapy use in a population-based sample of breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):617

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 617 Background: Previous studies have suggested underutilization and socioeconomic disparities in use of adjuvant radiotherapy (RT) among patients with breast cancer.
  • Rates of RT receipt were based on patient report.
  • These were then stratified based on recurrence risk in the absence of RT (3 groups based on tumor size and grade for DCIS pts, 2 groups separating pts over 70 with Stage I, ER+ tumors from others undergoing BCS for invasive disease, and 3 groups based on tumor size and nodal status for those undergoing mastectomy for invasive disease).
  • RESULTS: Among 306 pts undergoing BCS for DCIS, 85.6% received RT (77.9% of pts at low recurrence risk, 84.8% at intermediate risk, and 95.8% at high risk).
  • Among 1018 pts undergoing BCS for invasive disease, 93.6% received RT (83.6% of low-risk patients and 94.9% of others).
  • Among 661 pts undergoing mastectomy for invasive disease, 39.3% received RT (81.5% of pts at high-risk, 44.5% at intermediate-risk, and 12.1% at low risk).
  • In separate multivariate logistic regression models including risk grouping and sociodemographic variables for each population, there were no significant associations between RT receipt and race, education, or income.
  • Among pts receiving RT, delay was reported by 15.9% of the DCIS group, 19.5% of those treated for invasive disease after BCS, and 27.4% of those treated for invasive disease after mastectomy.
  • CONCLUSIONS: RT use is high after BCS with little evidence of socioeconomic disparities.
  • Less RT use in patients with lower expected benefit suggests that legitimate clinical uncertainty influences decision-making.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961489.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Lassman AB, Oligodendroglioma Study Group: Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors.
  • : 2014 Background: Treatment of anaplastic oligodendroglial tumors is controversial.
  • Early results of randomized trials suggest chemotherapy (CT) with procarbazine-lomustine-vincristine (PCV) before or after radiotherapy (RT) improves progression-free but not overall survival (OS) versus RT alone.
  • It is unknown if CT alone affects outcome versus CT&RT, or if temozolomide (TMZ) compares favorably with PCV.
  • Treatment was: observation (82, 8%), RT alone (n = 210, 20%), RT then chemotherapy (283, 27%), RT + CT concurrently (118, 11%), CT alone (205, 19%), CT then RT (137, 13%), or other (19, 2%).
  • Median time to progression (TTP) and OS were 2.8 and 6.5 years, respectively, with median follow up of 4.1 years (0.03-20.8) on surviving patients (n = 560, 53%).
  • 1p19q co-deletion was observed in 292 (48%) and no deletion in 232 (38%) of 606 tested tumors.
  • Median TTP was longer following CT&RT (sequential or concurrent) than CT alone (3.7 vs. 2.6 years, p = 0.0007), but median OS did not differ (6.6 vs. 7.1 years, p = 0.8); co-deletion was more common with CT alone than CT&RT (p < 0.0001, χ<sup><sup>2</sup></sup>), although restricting analysis of CT&RT versus CT to the co-deletion cohort yielded analogous results (median TTP 7.2 vs. 3.8 years, p = 0.011; OS 7.9 vs. 10.4 years, p = 0.26).
  • CT alone did not appear to shorten OS versus CT&RT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Yap JC, Yang GY, Fakih M, Mashtare T, Bullard Dunn K, Kuvshinoff BW, Smith J, Khushalani NI, Gibbs JF: Primary adenocarcinoma of the anus: a 22-year SEER population database analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e15072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the anus: a 22-year SEER population database analysis.
  • A search of the SEER database (1973 to 2005) was carried out to evaluate the pattern of radiation (RT) and surgical treatment.
  • METHODS: The search of the SEER database revealed 1,008 pts who had pathologically confirmed anal cancers with either SCCA or AdenoCa.
  • Within the SCCA group, 14 (1.5%) had abdominoperineal resection (APR) in combination with external beam RT, and 795 (83.3%) had RT only with non-APR local surgical treatment inclusive of excision.
  • Remaining 145 SCCA pts (15.2%) had non-APR local surgical treatment only without RT or had no treatment.
  • Within the AdenoCa group, 10 (18.5%) had APR in combination with external beam RT, and 21 (38.9%) had RT only with non-APR local surgical treatment inclusive of excision.
  • Remaining 23 AdenoCa pts (42.6%) had non-APR local surgical treatment only without RT.
  • Among the SCCA subset, there was no signficant difference in the 10-yr OS between the APR versus the RT pts (71% vs. 65%, p=0.78).
  • On the other hand, among the AdenoCa subset, pts who had APR had better 10-yr OS than RT pts (53.8% vs. 0%, p=0.03) Conclusions: For localized anal SCCA, RT yielded equivalent overall survival as compared to APR.
  • RT only without APR might not be sufficient treatment in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964572.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Arafat W, Abdelghany A, Awad N: A clinical trial to study the effect of adding cis-retinoic acid during and after conventional treatment for pediatric neuroblastoma patient. J Clin Oncol; 2009 May 20;27(15_suppl):10057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10057 Background: Neuroblastoma is predominantly a tumor of early childhood, with two thirds of the cases presenting in children younger than 5 years.
  • Patients who received cis-retinoic acid had significantly better 3-year event-free survival than patients receiving no maintenance therapy.
  • The aim of this study is to evaluate the efficacy of cis-retinoic acid when used in combination with conventional chemotherapy in pediatric patient who is newly diagnosed with locally advanced neuroblastoma.
  • METHODS: Seventeen newly diagnosed children with locally advanced neuroblastoma who is candidate to receive chemotherapy were also received cis-retinoic acid starting at a dose of 160 /m<sup>2</sup> day (day 2-15 of chemotherapy) first the 3 patients, 20% dose reduction were allowed if toxicity occurred in first cohort of patient. . Patients were giving the drugs for at least 4 cycles.
  • RT-PCR analysis of several related genes was done from tumor, sample after treatment.
  • Patients were stage III, IV (70%), II (30%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962453.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Huddart RA, James ND, Adab F, Syndikus I, Jenkins P, Rawlings C, Hendron C, Lewis R, Rogers S, Hall E, BC2001 Investigators: BC2001: A multicenter phase III randomized trial of standard versus reduced volume radiotherapy for muscle invasive bladder cancer (ISCRTN:68324339). J Clin Oncol; 2009 May 20;27(15_suppl):5022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5022 Background: Radiotherapy (RT) is an alternative to radical cystectomy in the management of muscle invasive bladder cancer.
  • Limitations are probability of attaining and maintaining local tumour control and risk of late bladder toxicity.
  • BC2001 tests whether concomitant chemotherapy (CT) improves loco-regional control and whether RT volume modification reduces late toxicity without detriment to tumour control.
  • METHODS: Pts were randomized in a 2x2 factorial design to (i) RT vs RT + concomitant CT (5FU 500mg/m<sup>2</sup> d1-5 wks 1 & 4 + mitomycin C 12mg/m<sup>2</sup> d1) and/or (ii) standard RT to tumour and whole bladder with 1.5cm margin (sRT) vs reduced volume RT (rvRT) where tumour + 1.5cm margin was treated to 100(±5)% target dose and remaining bladder received 80% target dose.
  • RT dose was 55Gy/20F or 64Gy/32F according to local practice.
  • RT volume comparison results (primary endpoint RTOG toxicity at 1 yr) are reported.
  • Target sample size was 480 pts but the RT randomisation closed early due to slow recruitment.
  • There was no difference in loco-regional disease-free survival (LRDFS: HR = 1.06, 95% CI: 0.62-1.84) nor overall survival (HR = 0.99, (0.61 - 1.35)) between randomised RT groups.
  • 2yr LRDFS is 71% in both RT groups.
  • CONCLUSIONS: RT in the modern era can attain local control in most patients with T2-T3 bladder cancer.
  • Modifying standard RT volumes had minimal effect on local control and toxicity in this trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962919.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Tosoni A, Franceschi E, Ermani M, Bacci A, Volpin L, Lombardo L, Ravenna G, Pinna G, Poggi R, Brandes AA: MGMT methylation status as a prognostic factor in anaplastic astrocytomas. J Clin Oncol; 2009 May 20;27(15_suppl):2052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated only pts who met the following inclusion criteria: age >18 years; PS 0-2; histological diagnosis of AA; postoperative radiotherapy (RT) and chemotherapy (CT).
  • The log-rank test was employed to evaluate the significance of the prognostic variables.
  • This datum should provide the background to improve the therapeutic index with temozolomide concurrent with and adjuvant to RT in AA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964674.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Greven K: Can serial PET/CT imaging during and after chemoradiation treatment assist in individualizing therapy for patients with squamous cell cancer of the head and neck? J Clin Oncol; 2009 May 20;27(15_suppl):e17022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17022 Background: PET/CT imaging with FDG has the potential advantage over conventional imaging of demonstrating metabolic changes in tumors early in the course of chemoradiation which may aid in individualization of therapy for patients.
  • METHODS: Sixteen patients with stage III/IV head and neck cancer were prospectively entered on a study to evaluate the role of PET/CT between March 2006 and July 2007.
  • The max standard uptake values (SUV) were recorded in the primary tumors.
  • In addition CT imaging was examined and the maximum dimensions of the primary tumor were recorded.
  • RESULTS: Three patients have recurred at the primary site and follow-up ranges from 15-30 months.
  • The change in SUV at 2 weeks, 4 weeks, post RT 6 weeks and 3 months compared to baseline for the 3 patients with local recurrence and the 13 patients who remain disease free were -7%, -62%, -50%, and -16% compared to -34%, -62%, -77%, and -81%, respectively.
  • In contrast CT imaging demonstrated that tumor measurements at 2 weeks, 4 weeks, post RT 6 weeks, and 3 months steadily decreased in both groups with mean changes in the recurrence group and in the locally controlled group of -11%, -46%, -77%, and -100% and -47%, -57%, -73%, and -99%, respectively.
  • CONCLUSIONS: Changes in SUV from PET/CT were significantly predictive of tumor recurrence compared to CT imaging alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961700.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Rudin CM, Senzer N, Stephenson J, Loesch D, Burroughs K, Police SR, Hallenbeck P: Phase I study of intravenous Seneca Valley virus (NTX-010), a replication competent oncolytic virus, in patients with neuroendocrine (NE) cancers. J Clin Oncol; 2009 May 20;27(15_suppl):4629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4629 Background: NTX-010 is a naturally occurring replication competent picornavirus with potent and selective tropism for human NE tumors, including small cell cancers and carcinoid.
  • NTX-010 elicts rapid cytolysis in vitro and durable responses following IV dosing in multiple xenograft models.
  • METHODS: A first-in-human phase I study of IV NTX-010 was conducted across 5 log-increment dose cohorts from 10<sup>7</sup> vp/kg to 10<sup>11</sup> vp/kg, in patients with NE cancers.
  • Evidence of intratumoral viral replication includes delayed kinetics in serum viral titer, post-infusion serum titers greater then the dose administered and positive immunohistochemistry and/or RT-PCR signal for viral antigens in tumor mass despite Ab production.
  • A single IV dose of 10<sup>11</sup> vp/kg of NTX-010 is safe, has predictable viral kinetics, and shows promising activity against NE tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N: GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). J Clin Oncol; 2009 May 20;27(15_suppl):4616

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary outcome is feasibility using proportion of patients (pts) receiving > 80% planned dose for each component.
  • METHODS: Pts with previously untreated inoperable LAPC, M0, measurable disease, ECOG 0-2 were given Gem (1000mg/m<sup>2</sup> d1 + d15 q28), Ox (100mg/m<sup>2</sup> d2 + d16 q28) in both ind (1 cycle) & con (3 cycles), & 5FU 200mg/m<sup>2</sup>/d over 6 weeks during RT of 54Gy in 30 fractions of 1.8Gy.
  • Worst grade (G) for anaemia (10%); fatigue, nausea (8%); diarrhoea, vomiting, neutropenia, infection (4%); stomatitis, anorexia (2%) was G3.
  • The extended duration of LC and a subset who had a very prolonged benefit may be due to patient selection but equally may suggest an incremental benefit from more intensive systemic therapy requiring further study in controlled trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964183.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Bhattacharyya S, Raina V, Shukla NK, Shukla S, Kumar R, Hedau S, Kumar G, Bharti AC, Rath GK, Das BC: Circulating tumor DNA in plasma of breast cancer patients from India. J Clin Oncol; 2009 May 20;27(15_suppl):e22213

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor DNA in plasma of breast cancer patients from India.
  • Recently, the level of cell free circulating tumor DNA in blood plasma or serum of patients with variety of tumors are being considered as reliable non-invasive diagnostic tool but no study has been done in India.
  • Concentration of cell free plasma DNA was analyzed by 3 methods viz. nanodrop spectro-photometry, integrated density value (IDV) of PCR products of Exon 7 of p53 gene and quantitative real time PCR (cycles threshold converted to genome equivalent).
  • RESULTS: Mean free plasma DNA concentration as determined by both Q-RT PCR and IDV in cancer patients was found to be significantly higher in advanced stage breast cancer patients than in controls (genome equivalent 18850 vs 431; IDV 17912 vs 4197; p=0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964168.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Selvaggi G, Righi L, Ceppi P, Bacillo E, Billè A, Pandiscia S, Ardissone F, Scagliotti GV, Papotti M: Relationship of thymidylate synthase levels to outcome of malignant pleural mesothelioma patients treated with pemetrexed-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):7508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of thymidylate synthase levels to outcome of malignant pleural mesothelioma patients treated with pemetrexed-based chemotherapy.
  • : 7508 Background: Pemetrexed has shown activity in malignant pleural mesothelioma (MPM) but scanty data are available on the expression of thymidylate synthase (TS), its most important molecular target.
  • In addition, mRNA extraction was performed in 23 micro-dissected tissues and TS relative levels quantified by RT-PCR.
  • Survival probability was assessed by Kaplan-Meier method and results compared by log-rank test.
  • RESULTS: Thirty-two patients had progressive disease and 24 had died at the time of the analysis.
  • Median time to progression (TTP) and median survival time (MST) were 11.6 and 20.9 months, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963478.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Comandone A, Boglione A, Pochettino P, Berno E, Inguì M, Papotti M, Borasio P, Maggi G, Brach Del Prever E, Gino G: Primary sarcomas of the lungs and mediastinum: Clinicopathological study and therapy results of Piedmontese Group for Sarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):e21509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcomas of the lungs and mediastinum: Clinicopathological study and therapy results of Piedmontese Group for Sarcomas.
  • : e21509 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • 5 mediastinal tumours were located as follows: 2 in anterior part, 1 in posterior and 2 in the middle (sarcomas of the heart).
  • RESULTS: In 20/31 cases the tumour was immediately resected (3 mediastinal masses and 17 lung sarcomas).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • CONCLUSIONS: Primary sarcomas of the lungs and mediastinum have a very severe prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Fusi A, Busse A, Ochsenreither S, Rietz A, Keilholz U: Expression of stem cell markers in circulating melanoma cells. J Clin Oncol; 2009 May 20;27(15_suppl):e22056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22056 Background: Within circulating tumor cells there may be a subset of cell with stem cell (tumor initiating) characteristics able to develop distant metastasis.
  • METHODS: Between 50 and 100 ml of peripheral blood were collected from 12 melanoma patients with various tumor burden as well as three healthy volunteers.
  • Blood samples were enriched for tumour cells by CD45 depletion of the leukocyte fraction using magnetic beads separation (EasySep, Stem Cell Technologies. Inc.).
  • The remaining material was stained with antibodies for the markers Melan-A/Mart-1 (Dako) and HMB45 (Dako), CD133 (Miltenyi Biotec) and nestin (R&D System) and analysed by flow cytometry (BD FACSCalibur).
  • Ten ml of blood were further processed and CD133, nestin, Melan-A/Mart-1 transcripts were quantified by Real Time RT-PCR (LightCycler, Roche Diagnostic).
  • The population of cells with lower expression of the melanoma markers showed at the same time higher expression of nestin and CD133 (5.9% vs. 1.3% and 10.2% vs. 6.7% respectively).
  • Nestin results were in good accordance to the FACS data (nestin: r=0.55; CD133: r=0.23; Pearson test).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963238.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. El-Khoueiry AB, Pohl A, Danenberg K, Cooc J, Zhang W, Yang D, Singh H, Shriki J, Iqbal S, Lenz HJ: Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). J Clin Oncol; 2009 May 20;27(15_suppl):4056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue samples from 68 patients with mCRC were analyzed. mRNA was extracted from laser-capture-microdissected tumor tissue. cDNA was prepared by reverse transcription and quantitation of the candidate genes was performed using a fluorescence- based real-time detection method (TaqMan).
  • Allele specific RT-PCR was performed to determine Kras mutation status in codons 12 and 13.
  • CONCLUSIONS: To our knowledge, this is the first report of a potential association between Kras status as well as gene expression levels of VEGFR2, ERCC-1 and EGFR and clinical outcome to FOLFOX/BV therapy in pts with mCRC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Simonelli M, Banna G, Navarria P, Di Ieva A, Zucali P, De Vincenzo F, Gaetani P, Condorelli R, Rodriguez Y Baena R, Scorsetti M, Santoro A: Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13037 Background: Anaplastic astrocytoma (AA), oligodendroglioma (AOD), and oligoastrocytoma (AOA) are rare tumors showing variable outcome due to their histological heterogeneity and different chemo- and radio-sensitivity.
  • Currently, the addition of chemotherapy to radiotherapy (RT) for newly diagnosed anaplastic gliomas is not sustained by available data.
  • METHODS: Since September 2004, following initial surgery, patients (pts) with histologically confirmed anaplastic glioma, Karnofsky Performance Status (KPS) ≥40, adequate organ function, no prior chemotherapy, were treated with RT to limited fields once daily at 2 Gy per fraction, 5 days a week, for a total of 60 Gy with concomitant TMZ (75 mg/m<sup>2</sup> for 7 days a week) followed by 6 cycles of maintenance TMZ at 200 mg/m<sup>2</sup> on days 1-5 every 28 days.
  • Nine pts (32%) underwent tumor complete resection, 10 partial resection (36%), and 9 (32%) tumor biopsy.
  • In 1 patient with AOD RT and concomitant TMZ were interrupted at 44 Gy because of cerebral oedema, while in 1 patient with AA maintenance TMZ was suspended due to cumulative myelosuppression.
  • Frequent mild toxicities were grade 1-2 nausea/vomiting (17 pts-63%), and grade 1-2 asthenia (8 pts-30%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Perez SA, Bisias S, Kallinteris NL, Ardavanis A, Georgakopoulou KG, Apostolikas N, Thanos A, Papamichail M, von Hofe E, Baxevanis CN: Results from the first phase I clinical study of the novel Ii-Key/HER2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All pts had standard treatment prior to vaccinations, including surgery (S) (n=9); hormonal treatment (HT) (n=4); S+HT (n=6); S+HT+radiotherapy (RT); (n=2); S+chemotherapy (CH) (n=2); HT+RT (n=2); CH (n=3) and S+HT+CH (n=2).
  • During vaccinations, 11 pts were free of any treatment, while 5 pts who had progressive disease received additional chemotherapy; the remainder received HT alone or combined with RT.
  • Toxicity and side effects beyond grade-2 were not observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962063.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Kurosumi M, Kobayashi Y, Takei H: The utility of a real-time RT-PCR assay for the detection of metastases greater than 0.2 mm in sentinel lymph nodes of breast cancer patients confirmed by detailed histological analysis. J Clin Oncol; 2009 May 20;27(15_suppl):628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of a real-time RT-PCR assay for the detection of metastases greater than 0.2 mm in sentinel lymph nodes of breast cancer patients confirmed by detailed histological analysis.
  • : 628 Background: Analysis using real time RT-PCR for the detection of metastases in lymph nodes (LN) increases sampling but is associated with a risk of too much sensitivity as compared to histological analysis.
  • Determining the appropriate cutoff value is important in introducing this system to routine clinical practice.
  • Our study confirms the reliability of the cutoff values of a real-time RT-PCR assay (GeneSearch, Veridex LLC) to detect metastases larger than 0.2 mm by detailed 0.2 mm frozen section histological diagnosis.
  • All remaining tissue between the histology sections was assayed by the real-time RT-PCR assay using the genetic markers mammaglobin (MG) and cytokeratin-19 (CK-19) (note: tissue processing method was investigational and off-label).
  • RESULTS: Compared to the histological diagnosis using 0.2 mm interval frozen sections, the real-time RT-PCR results were as follows; sensitivity of 100.0% (34/34), specificity of 93.7% (89/95), and overall accuracy of 95.3% (123/129).
  • Submicrometastases were recognized by IHC in 3 of 95 samples (2 solitary and 1 multiple sites) diagnosed as negative by H&E-stain sections, and 3 samples were negative for RT-PCR.
  • CONCLUSIONS: Results of 0.2 mm interval histological analysis suggest a near perfect sensitivity of the real time RT-PCR assay, allowing reliable detection of LN metastases larger than 0.2 mm.
  • In addition, at least three samples with submicrometastases detected by immunohistochemistry for pancytokeratin were above the preset cutoff values of this real time RT-PCR assay.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961430.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Dandona MA, Morgensztern D, Auethavekiat V, Adkins D, Thorstad W, Nussenbaum B, Zhang Q, Kuperman DI: Survival for nasopharyngeal cancer with distant metastatic disease at presentation. J Clin Oncol; 2009 May 20;27(15_suppl):e17004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17004 Background: Nasopharyngeal carcinoma (NPC) is a unique form of head and neck cancer, with distinct epidemiology and sensitivity to chemotherapy (CT) and radiation (RT).
  • METHODS: The SEER database was searched for patients with NPC who have distant metastatic disease at presentation, defined as extent of disease (EOD10) code 85, aged 20 or older, diagnosed between 1988 and 2003.
  • Survival probability was estimated by Kaplan-Meier method and covariate effects were examined using log-rank tests.
  • Parameters evaluated include age, gender, race, tumor grade, and use of RT.
  • Five patients were excluded from subsequent analysis because RT data was not available.
  • RT was administered to 114 patients (66.3%).
  • Outcomes were significantly improved for patients treated with RT compared to those not receiving it, with the 5-year OS rates of 28% versus 3% (p < 0.0001) respectively.
  • CONCLUSIONS: Although SEER lacks information on performance status, site of metastases, and CT use, our data shows that selected patients with metastatic NPC may achieve prolonged survival, particularly if RT is used.
  • It is unclear whether RT is a determinant of better OS or an epiphenomenon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961652.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Mir AR Jr, Sazawal Sazawal S, Saxena A, Saxena R: High-sensitivity detection of M351T, F317L, and F311C BCR-ABL kinase domain mutation in chronic myeloid leukemia patients treated with novel tyrosine kinase inhibitors (TKIs) imatinib and dasatinib. J Clin Oncol; 2009 May 20;27(15_suppl):7061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred CML patients were treated with imatinib at 400 mg/day from 2 to 4 years .They were diagnosed by RT-PCR for BCR-ABL transcripts.
  • After 11 months of dose escalation, 15/20 lost M351T mutation but remaining five who resist M351T mutation, developed a more fatal mutation called gate keeper mutation T315I.
  • CONCLUSIONS: ASO-PCR proved to be a very economical, sensitive, and rapid technique for detection of KD mutations M351T, F317L, and F311C ABL mutation and is more sensitive than mutation detection by sequencing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Nicholas MK, Lucas RV, Arzbaecher J, Paleologos N, Krouwer H, Malkin M, Omar A, Vick NA: Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):2016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II study.
  • : 2016 Background: Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor.
  • Current standard treatment consists of fractionated radiotherapy (RT) with daily oral temozolomide (TMZ) chemotherapy followed by 6 months of adjuvant TMZ chemotherapy.
  • Because GBM is characterized by vascular proliferation and produces high levels of vascular endothelial growth factor (VEGF), attempts to better control the disease with targeted anti-angiogenesis therapies are underway.
  • METHODS: Subjects received standard regional RT to a dose of 60 Gy in 30 fractions with dailyconcurrent TMZ (75 mg/m2) within 3-5 weeks of diagnosis.
  • Four weeks after RT/TMZ, subjects received 5 consecutive daily TMZ doses (150-200 mg/m2) administered every 28 days.
  • Of these, 4 were receiving RT/TMZ, 18 were receiving TMZ/BV and 1 was delayed post-RT/TMZ due to local wound infection.
  • Eleven of those off-study never received BV due to: study withdrawal (n = 2), toxicity during RT/TMZ (n = 3) and post-RT/TMZ progression (n = 6).
  • Duration of treatment, inclusive of RT/TMZ, ranged from 27 to 523 days.
  • CONCLUSIONS: The co-administration of TMZ/BV following RT/TMZ for newly diagnosed GBM is safe and well-tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964582.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Drappatz J, Norden AD, Wong ET, Lassman AB, Doherty L, LaFrankie D, Gerard M, Phan P, Schiff D, Wen PY: Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):2031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2031 Background: There is increasing evidence that angiogenesis inhibition may potentiate the effects of radiation therapy (RT) and chemotherapy in patients with glioblastoma (GBM).
  • In addition, inhibition of the epidermal growth factor receptor (EGFR) may be of therapeutic benefit, as EGFR is often upregulated in GBM and contributes to radiation resistance.
  • We conducted a phase I study of vandetanib, an inhibitor of VEGFR2 and EGFR, in patients with newly-diagnosed GBM in combination with RT and temozolomide (TMZ).
  • METHODS: Using a standard 3 + 3 dose escalation design, 13 newly-diagnosed GBM patients received vandetanib with RT (60 Gy) and concurrent TMZ 75 mg/m<sup>2</sup> daily, followed by adjuvant TMZ for up to 12 cycles (150-200 mg/m<sup>2</sup> on days 1-5 of each 28 day cycle).
  • 2/6 patients developed DLTs (grade 5 gastrointestinal hemorrhage and grade 3 thrombocytopenia in one patient and grade 4 neutropenia in one patient).
  • CONCLUSIONS: These data suggest that vandetanib may be combined with RT and TMZ in GBM patients.
  • A randomized phase II study in which patients receive RT and TMZ with or without vandetanib 100 mg daily is underway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964631.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Schuetze S, Rutkowski P, Van Glabbeke MM, Rankin C, Rubin BP, Lazar A, Debiec-Rychter M, Gelderblom H, Hohenberger P, van Oosterom AT: Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP). J Clin Oncol; 2009 May 20;27(15_suppl):10520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10520 Background: DFSP is an infiltrative, low-grade, dermal tumor with propensity to recur locally and occasionally metastasize.
  • Two distinct phase II trials of imatinib in patients (pts) with locally advanced or metastatic DFSP were conducted, 1 in North America (SWOG) with confirmed objective response rate and 1 in Europe (EORTC) with 14 week progression-free rate as primary end-points.
  • In the SWOG trial confirmation of t(17;22) by RT-PCR was performed after enrollment, imatinib was started at 400mg daily and response was assessed every 8 weeks.
  • One patient did not have DFSP on central review, lacked t(17;22) and thus was ineligible.
  • Median time to progression was 1.7 yrs.
  • Response rates and time to progression did not appear to differ between pts taking 400 mg daily versus 400 mg bid.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963939.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Tjan-Heijnen VC, Pepels MJ, de Boer M, Borm GF, van Dijck JA, van Deurzen CH, Adang EM, Menke-Pluymers MB, van Diest PJ, Bult P: Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study. J Clin Oncol; 2009 May 20;27(15_suppl):CRA506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963471.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Cabrera A, Jantus Lewintre E, Sirera R, Honguero A, Gil M, Blasco A, Sanmartin E, Arnau A, Guijarro R, Camps C: Expression of angiogenic genes in resectable non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e22207

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is known that angiogenesis is an essential event for solid tumour growth.
  • Vascular endothelial growth factor (VEGF) family of ligand and receptors (VEGFR) are described as powerful angiogenic factors.
  • METHODS: We performed real-time quantitative polymerase chain reaction (RT-qPCR) to assess the expression of VEGF, PlGF, VEGFR1 and VEGFR2 in frozen lung cancer specimens from untreated NSCLC patients who had undergone surgical resection (n=21).
  • RESULTS: Our results show that tumor samples have higher expression of PlGF than normal tissue.
  • We found a significant correlation between the levels of expression of PlGF and the tumor size (p= 0.023, Spearman's test), whereas no relation was found between the expression of the genes and the histology or stage of disease.
  • CONCLUSIONS: Our results reveal that, in NSCLC, PlGF mRNA is higher in tumor than in normal tissue and is positively correlated with the tumor size and with the expression of angiogenic receptors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964135.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Indelicato DJ, Keole SR, Shahlaee AH, Morris CG, Gibbs CP, Scarborough MT, Islam S, Marcus RB: Ewing tumors of the chest wall: Local control and long-term outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):e21501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing tumors of the chest wall: Local control and long-term outcomes.
  • : e21501 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • 5 mediastinal tumours were located as follows: 2 in anterior part, 1 in posterior and 2 in the middle (sarcomas of the heart).
  • RESULTS: In 20/31 cases the tumour was immediately resected (3 mediastinal masses and 17 lung sarcomas).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • CONCLUSIONS: Primary sarcomas of the lungs and mediastinum have a very severe prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Yamada Y, Yamamoto S, Ohtsu A, Suzuki Y, Nasu J, Yamaguchi K, Denda T, Tsuji A, Hara Y, Boku N, Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group: Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. J Clin Oncol; 2009 May 20;27(15_suppl):4535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Blocks from endoscopic biopsy specimens of primary lesions before chemotherapy were available from 365 of 704 pts in JCOG9912.
  • Using laser-captured microdissection and real-time RT-PCR, we analyzed mRNA expression of ERCC1, TS, DPD in paraffin-embedded specimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962991.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Chilukuri S, Surana S, Mohanty PP, Kuppuswamy R: Impact of interobserver variability in delineating clinical target volumes (CTV) for head and neck intensity modulated radiation therapy (IMRT): Potential for a geographical miss. J Clin Oncol; 2009 May 20;27(15_suppl):e17013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: This study documents that the volumes of uncertainty surrounding the PTV, which could contain subclinical disease, in fact receive a significant amount of RT dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961730.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Seitz S, Schally AV, Gluck S, Rick F, Szalontay L, Hohla F, Papadia A, Köster F, Ortmann O, Buchholz S: Effective treatment of triple-negative breast cancer with targeted cytotoxic somatostatin analogue AN-162 (AEZS-124). J Clin Oncol; 2009 May 20;27(15_suppl):619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression of SSTR in HCC 1806 human TNBC cell line was detected by RT-PCR.
  • In vivo, AN-162 significantly (p<0.05) inhibited tumor growth of HCC 1806 xenografts compared to Control, DOX and the unconjugated mixture of DOX+RC-160 from day 14 and the inhibition remained significant until the end of the study on day 35.
  • CONCLUSIONS: Our results indicate that treatment with targeted cytotoxic somatostatin analogue AN-162 produces a greater inhibition of tumor growth than DOX alone in somatostatin receptor positive TNBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961493.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Kronenwett R, Stropp U, Briasoulis E, Gehrmann M, Razis E, Hennig G, Bafaloukos D, Wirtz RM, Economopoulos T, Fountzilas G: Utility of a multigene prognostic algorithm in combination with TP53 expression for prediction of benefit from adjuvant taxane-containing chemotherapy in node-positive breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):593

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of a multigene prognostic algorithm in combination with TP53 expression for prediction of benefit from adjuvant taxane-containing chemotherapy in node-positive breast cancer patients.
  • METHODS: The 211 N+ patients included in this study were treated in the context of a randomized two-arm phase III study (E-T-CMF vs. E-CMF) investigating adjuvant dose-dense sequential chemotherapy with epirubicin (E) followed by CMF with or without paclitaxel (T).
  • RNA was isolated from formalin-fixed, paraffin-embedded tissue samples, using a Siemens proprietary method, followed by kinetic one-step RT-PCR for assessment of mRNA expression of the nine SPS genes, TP53 and two normalization genes.
  • Optimal cutoff for low or high TP53 expression was defined on the basis of a ROC curve in SPS high-risk patients.
  • Distant metastasis-free survival (MFS) and overall survival (OS) were estimated by the Kaplan-Meier method and compared using the log-rank test.
  • CONCLUSIONS: Our prognostic algorithm combined with TP53 mRNA expression predicts the benefit from the addition of paclitaxel to E-CMF and might be used for identification of patients who should be considered for adjuvant taxane therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960707.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Tanja FN, Hoffmann O, Aktas B, Solomayer E, Wallwiener D, Becker S, Kimmig R, Kasimir-Baur S: Expression profile of CTC and corresponding tumors in primary breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of CTC and corresponding tumors in primary breast cancer patients.
  • However, treatment decisions are based on expression of predictive markers (ER; PR, HER-2) of the primary tumor.
  • Based on current studies, presence of MRD may be reflected by the detection of circulating tumor cells (CTC).
  • Therefore, the aim of the study was to characterize CTC by multiplex-PCR for the expression of HER-2, ER, and PR and compare the expression profiles of CTCs with those of the corresponding primary tumors.
  • METHODS: CTC from blood of 431 patients with primary breast cancer were analyzed for EpCAM, MUC1, and HER-2 transcripts with the AdnaTest BreastCancer (AdnaGen AG, Germany).
  • Expression of the ER and PR receptor was assessed in an additional RT-PCR.
  • The ER, PR and HER2 receptor status of the primary tumors was determined by immunohistochemistry.
  • ER positivity of the primary tumor was demonstrated in 45/58 (78%) of these patients, PR positivity in 41/58 (71%) patients and HER-2 in 9/58 (16%) patients, respectively.
  • The concordance rate between ER, PR, and HER-2 status of CTCs and the primary tumor was 29%, 25%, and 53%, respectively Interestingly, the spread of CTC was mostly found in triple negative tumors (p = 0.01) and CTC in general were mostly found to be triple-negative regardless of the ER, PR, and HER-2 status of the primary tumor.
  • CONCLUSIONS: Since the expression profile between CTC and the primary tumor differs, the consequence for the selection of adjuvant treatment targeting minimal residual disease has to be further evaluated in clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960691.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Sharma D, Knight BB, Yacoub R, Liu T, Taliaferro-Smith L, Nagalingam A, O'Regan RM: Using epigenetic reprogramming to target triple-negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e14565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since all endocrine therapies are designed to block ER function in some way, the identification of new therapies or strategies that could sensitize TN breast cancers to existing endocrine therapy could provide a revolutionary means of treating this aggressive subtype of cancer Methods: We examined the efficacy of combined treatment of HDAC inhibitor LBH589 and DNMT inhibitor decitabine to regenerate ER and PR in TN breast cancer cells using RT-PCR and immunoblotting.
  • Tumors biopsies were analyzed for ER and PR re-expression by western blot analysis and immunohistochemistry at the end of the treatment.
  • CONCLUSIONS: The importance of epigenetic events such as DNA methylation and HDAC inhibition in tumor progression is becoming increasingly evident.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963687.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Quesenberry PJ, Del Tatto M, Berz D, Miner T, Ng T, Winer ES, Aliotta J, Colvin G, Dooner M, Dooner G, Fontaine JP: Marrow cell genetic phenotype change induced by human lung cancer cells. J Clin Oncol; 2009 May 20;27(15_suppl):11108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minced tumor tissue at 50-100 mg was co-cultured in a semi-permeable culture plate insert opposite 3.0 ×10<sup>6</sup> human marrow cells.
  • Marrow cell RNA was analyzed for lung specific mRNA using real time RT-PCR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963460.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Park K, Ahn Y, Chen M, Cho E, Kim J, Min Y, Kim H, Zhu G, Heo DS, Wu Y: A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN): Interim analysis. J Clin Oncol; 2009 May 20;27(15_suppl):7538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CCRT with D (20 mg/m<sup>2</sup>) and P (20 mg/m<sup>2</sup>) was administered every week for 6 weeks with a total dose of 66 Gy of thoracic RT as 33 fractions.
  • The primary endpoint is time to progression (TTP).
  • Total target number of patients is 458.
  • Grade 3-4 neutropenia occurred in 5.4% of 203 consolidation cycles.
  • At the time of this analysis, there were 40 and 41 deaths in the observation and consolidation arms, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963307.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Goldkorn A, Xu T: Targeting prostate cancer progenitor cells with telomerase interference: A novel therapeutic strategy. J Clin Oncol; 2009 May 20;27(15_suppl):e22029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22029 Background: We investigated whether telomerase, which is critical for benign stem cell activation, also plays a role in prostate cancer progenitor cells (PCPCs), which are thought to mediate therapy resistance and cancer progression, and we tested whether telomerase interference can effectively inhibit PCPC proliferation.
  • PCPCs were characterized for gene expression (RT-PCR), clonogenicity (colony formation), invasiveness (matrigel chamber), and telomerase activity (qPCR-TRAP).
  • RESULTS: An integrin α<sub>2</sub>β<sub>1</sub><sup>+</sup>CD<sub>44</sub><sup>+</sup> putative PCPC population was isolated from 6 human prostate tumors.
  • CONCLUSIONS: We have shown that human prostate tumors contain a subpopulation of prostate cancer progenitor cells (PCPCs) marked by an undifferentiated gene expression profile, vigorous clonogenicity and invasiveness, and high levels of telomerase activity that can be successfully exploited to neutralize these cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963140.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Power DG, Jhawer M, Feilchenfeldt JW, Kelsen DP, Shah MA: Metastatic gastroesophageal cancer and long-term survival. J Clin Oncol; 2009 May 20;27(15_suppl):4560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4560 Background: Despite modest therapeutic improvements, resistance to systemic chemotherapy develops in most pts with advanced gastric/GEJ (GE) adenocarcinoma.
  • We describe clinicopathological characteristics of a large cohort of long term survivors(LTS) with metastatic GE adenocarcinoma.
  • METHODS: Our institutional database of pts with GE adenocarcinoma who received chemotherapy between 1999-2008 identified 103 pts with metastatic disease (M1) surviving >2 years from M1.
  • From the time of M1, 103 pts (9%) lived >2 yrs.
  • Tumors were located at GEJ/cardia (n=52), body/fundus (n=29), antrum/pylorus (n=22), and were mainly poorly differentiated (n=61).
  • Surgery was performed in 28 pts, 26 gastrectomies (15 with occult peritoneal M1, 11 once peritoneal M1 cleared) and 2 metastatectomies; 7 pts received RT(6 to primary, 1 to M1 site).
  • We are now exploring tumor and normal tissue from LTS versus matched controls (survival <1 year) for molecular/genomic correlates for LTS No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963060.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement